1	Keeping up with the pathogens: Improved antimicrobial resistance detection and
2	prediction from Pseudomonas aeruginosa genomes
3	
4 5	Danielle E. Madden ^{1,2} , Timothy Baird ^{1,2,3} , Scott C. Bell ^{4,5} , Kate L. McCarthy ^{6,7} , Erin P. Price ^{1,2*} and Derek S. Sarovich ^{1,2*#}
6	
7	1 Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia
8	² Sunshine Coast Health Institute, Birtinya, Queensland, Australia
9	³ Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia
10	4 Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, Queensland, Australia
11 12	⁵ Children's Health Research Centre, Faculty of Medicine, The University of Queensland, South Brisbane, Queensland, Australia
13	6 University of Queensland Centre for Clinical Research, Herston, Queensland, Australia
14	⁷ Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
15	
16 17	Keywords: Antibiotic, genomics, high-throughput sequencing, bioinformatics, AMR database, metagenomics, whole-genome sequencing, AMR software, AMR prediction
18	
19	Running title: AMR detection from <i>P. aeruginosa</i> genomes
20	
21	#Corresponding author:
22	Derek S. Sarovich
23	<u>dsarovich@usc.edu.au</u> ; +61 7 5456 3748

24 *Authors contributed equally

25 Abstract

26	Background: Antimicrobial resistance (AMR) is an intensifying threat that requires urgent mitigation to
27	avoid a post-antibiotic era. The ESKAPE pathogen, <i>Pseudomonas aeruginosa</i> , represents one of the
28	greatest AMR concerns due to increasing multi- and pan-drug resistance rates. Shotgun sequencing is
29	quickly gaining traction for <i>in silico</i> AMR profiling due to its unambiguity and transferability; however,
30	accurate and comprehensive AMR prediction from <i>P. aeruginosa</i> genomes remains an unsolved
31	problem.
32	<i>Methods:</i> We first curated the most comprehensive database yet of known <i>P. aeruginosa</i> AMR
33	variants. Next, we performed comparative genomics and microbial genome-wide association study
34	analysis across a Global isolate Dataset (<i>n</i> =1877) with paired antimicrobial phenotype and genomic
35	data to identify novel AMR variants. Finally, the performance of our <i>P. aeruginosa</i> AMR database,
36	implemented in our ARDaP software, was compared with three previously published in silico AMR
37	gene detection or phenotype prediction tools – abritAMR, AMRFinderPlus, ResFinder – across both the
38	Global Dataset and an analysis-naïve Validation Dataset (<i>n</i> =102).
39	Results: Our AMR database comprises 3639 mobile AMR genes and 733 AMR-conferring chromosomal
40	variants, including 75 chromosomal variants not previously reported, and 284 chromosomal variants
41	that we show are unlikely to confer AMR. Our pipeline achieved a genotype-phenotype balanced
42	
	accuracy (bACC) of 85% and 81% across 10 clinically relevant antibiotics when tested against the
43	accuracy (bACC) of 85% and 81% across 10 clinically relevant antibiotics when tested against the Global and Validation Datasets, respectively, vs. just 56% and 54% with abritAMR, 58% and 54% with
43 44	
	Global and Validation Datasets, respectively, vs. just 56% and 54% with abritAMR, 58% and 54% with
44	Global and Validation Datasets, respectively, vs. just 56% and 54% with abritAMR, 58% and 54% with AMRFinderPlus, and 60% and 53% with ResFinder.
44 45	Global and Validation Datasets, respectively, vs. just 56% and 54% with abritAMR, 58% and 54% with AMRFinderPlus, and 60% and 53% with ResFinder. Conclusions: Our ARDaP software and associated AMR variant database provides the most accurate
44 45 46	Global and Validation Datasets, respectively, vs. just 56% and 54% with abritAMR, 58% and 54% with AMRFinderPlus, and 60% and 53% with ResFinder. <i>Conclusions:</i> Our ARDaP software and associated AMR variant database provides the most accurate tool yet for predicting AMR phenotypes in <i>P. aeruginosa</i> , far surpassing the performance of current
44 45 46 47	 Global and Validation Datasets, respectively, vs. just 56% and 54% with abritAMR, 58% and 54% with AMRFinderPlus, and 60% and 53% with ResFinder. <i>Conclusions:</i> Our ARDaP software and associated AMR variant database provides the most accurate tool yet for predicting AMR phenotypes in <i>P. aeruginosa</i>, far surpassing the performance of current tools. Implementation of our ARDaP-compatible database for routine AMR prediction from <i>P</i>.

51 Background

52	Antibiotic overuse and misuse [1] has driven the emergence of antimicrobial-resistant (AMR)
53	pathogens globally [2]. We are now on the verge of a 'post-antibiotic era', where simple infections
54	threaten to be untreatable with antimicrobials that once revolutionised modern medicine [3]. If
55	unmitigated, AMR infections are predicted to cause 10 million deaths globally by 2050 and cost
56	USD\$100 trillion per annum [4].
57	The ESKAPE pathogen, <i>Pseudomonas aeruginosa</i> , represents one of the biggest AMR threats due to its
58	intrinsic resistance towards many antibiotics, environmental ubiquity, ability to infect a wide spectrum
59	of hosts, and high global mortality rate [5-7]. Accurately detecting and predicting AMR phenotype
60	from genotype in <i>P. aeruginosa</i> has proven challenging [8], even using machine learning approaches
61	[9], with some approaches as accurate as a coin flip [8]. A major shortcoming of current in silico AMR
62	tools is that they largely focus on detecting AMR gene gain [10, 11] and a small number of
63	chromosomally encoded single-nucleotide polymorphisms (SNPs) [12-14]. However, P. aeruginosa can
64	also evolve AMR through chromosomal insertions-deletions (indels), loss-of-function mutations (e.g.
65	large deletions or frameshift mutations), structural variants, and copy-number variations (CNVs) [15].
66	Despite recent advances [11, 12], most AMR tools remain limited in their scope and accuracy [16] – for
67	example, loss-of-function mutations, a major contributor to AMR, are largely ignored [14], AMR
68	databases are often not species-specific [14, 17], they do not resolve to the individual antibiotic level
69	[11], and precursor mutations conferring reduced antimicrobial susceptibility are overlooked. These
70	limitations are especially problematic for accurate AMR detection and prediction in pathogens
71	encoding complex resistomes like <i>P. aeruginosa</i> [8].
72	To address this gap, we curated and validated the most comprehensive <i>P. aeruginosa</i> -specific AMR
73	variant database yet, which, when used in conjunction with the Antimicrobial Resistance Detection
74	and Prediction (ARDaP) software [14], enables high-accuracy AMR prediction from P. aeruginosa
75	genomes. Performance of our ARDaP-compatible AMR variant database was first assessed across 1877
76	diverse <i>P. aeruginosa</i> strains ("Global Dataset"), and subsequently, across 102 analysis-naïve <i>P.</i>

- 77 *aeruginosa* strains ("Validation Dataset"). Our approach, which we demonstrate far exceeds the
- 78 performance to current AMR prediction software, provides a crucial steppingstone towards the
- routine clinical use of genomics and metagenomics to inform personalised *P. aeruginosa* antimicrobial
- 80 treatment regimens.

81 Methods

- 82 *P. aeruginosa* AMR variant database construction. To cover the spectrum of AMR variants found in *P.*
- 83 *aeruginosa*, an ARDaP v1.9 [14] compatible SQLite database was populated with all known AMR
- 84 variants described in this pathogen to date
- 85 (https://github.com/dsarov/ARDaP/blob/master/Databases/Pseudomonas aeruginosa pao1/). Gene
- 86 names, locus tags, and genomic coordinates in our AMR variant database were based on PAO1
- 87 (NC_002516.2) [18]. An exhaustive literature search was conducted to encompass biomedical
- 88 literature published from 1980 to April 20th 2023 within the MEDLINE database. Search terms included
- 89 "antimicrobial resistance" and "P. aeruginosa" accompanied by a variable search term for targeted
- 90 literature, and included either: i) antibiotic class (e.g. carbapenem, aminoglycoside); ii) AMR
- 91 mechanism (e.g. efflux, gene expression enzymatic inactivation); or iii) a known AMR gene (e.g. oprD,
- 92 *ampC*, *gyrA*).
- 93 The resultant *P. aeruginosa* AMR database (Dataset 1) consists of three tables. The first table, '1.
- 94 Antibiotics', lists the ten clinically relevant antibiotics that were interrogated in our study: amikacin,
- 95 cefepime, ceftazidime, ciprofloxacin, colistin, imipenem, meropenem, piperacillin,
- 96 piperacillin/tazobactam, and tobramycin, whether these drugs are first-line, second-line or tertiary,

97 and their associated antibiotic class. The second ('2. Variants_SNP_indel') and third ('3. Coverage')

tables list the entire *P. aeruginosa* mutational resistome [19, 20], which includes all known genetic

99 alterations that can lead to AMR, including the functional loss of chromosomal genes (under, '3.

100 Coverage'). These databases include all AMR variants and genes that: i) cause efflux pump

101 upregulation [21]; ii) alter outer membrane permeability [22]; iii) de-repress or alter the substrate

range of the AmpC cephalosporinase [23]; and/or iv) alter the antimicrobial target [24]. AMR gene

acquisition was interrogated with ResFinder v4.0 [25], using default parameters and retaining only

104 genes identified at 100% similarity and with 100% coverage. Resfinder is integrated within the ARDaP

- 105 tool and run as part of the default pipeline. The default ResFinder database was manually curated to:
- 106 1) remove false-positive hits that were consistently identified in AMR sensitive strains; *bla*_{OXA-}

107	395 1 AY306133,	bla _{OXA-396} 1	_{AY306134} , blc	РАО 4 АУО83592,	bla _{pao 1 ayo}	₀₈₃₅₉₅ , bla _{РАО З FJ}	666073, bla _{PAO 2 FJ666065} , and
-----	-----------------	--------------------------	---------------------------	-----------------	--------------------------	---	---

- 108 *crpP*_HM560971; 2) include additional gene variants identified within the Global Dataset in
- aminoglycoside AMR-conferring genes *aac*(6')-lb, *aac*(6')-lla, *aac*(6')-lb-cr, and *aac*(3)-llla; and 3) as per
- 110 ResFinder recommendations for *P. aeruginosa*, the substrate range for *bla*_{OXA-2_1_DQ112222} and *bla*_{OXA-}
- 111 2_2_GQ466184 was expanded to include meropenem and imipenem.
- 112 For the aminoglycosides (i.e. amikacin and tobramycin), known AMR variants consisted of point
- 113 mutations in *algA* [26], *amgS* [27], *fusA1* [26, 28-33], *rplB* [34], *ptsP* [33, 35], and *tuf1* [26], and loss-of-
- 114 function mutations in the nuo [36-38] pathway. For the carbapenems (i.e. imipenem and meropenem),
- 115 cephalosporins (i.e. ceftazidime), and β-lactams with or without an inhibitor (i.e. piperacillin and
- 116 piperacillin/tazobactam), mutations that alter or expand the substrate range of the *ampC*
- 117 cephalosporinase [23, 39-42] or that alter *ampC* expression, including inactivation of penicillin-
- 118 binding-protein 4 (PBP4; dacB) [43-45], ampD [45-47], ampDh2 [47], ampDh3 [47], ampE [47], ampR
- 119 [48, 49], mpl [50], or ampC-ampR intergenic region [51], mutations in PBP3 (ftsl) [48, 52, 53], and
- 120 mutations that cause oprD loss, inactivation, or down-regulation [49, 54-60], were included. For
- 121 ciprofloxacin AMR prediction, we included point mutations in gyrA [61-67], gyrB [62, 63, 65, 68], parC
- 122 [61-63, 66], and parE [62, 63, 65]. For colistin AMR prediction, point mutations in cprS [52], pmrA [69],
- 123 *pmrB* [31, 69-74], *phoP* [69], and *phoQ* [69] were included.

124 Efflux pumps play a key role in AMR development in *P. aeruginosa*, predominantly through regulator

alterations, which drive efflux pump overexpression [15]. To predict MexAB-OprM upregulation, which

126 is associated with β-lactam (including carbapenem) AMR [21], we included mutations in the *cis* (*mexR*

127 [29, 61, 64, 75, 76]) and *trans* (*nalC* [77, 78] and *nalD* [23, 71, 77-79]) regulators of this efflux pump.

- 128 For MexCD-OprJ upregulation, which is associated with fluoroquinolone and specific β-lactam AMR
- 129 [21], mutations and loss-of coverage in the single known regulator, *nfxB* [61, 64] were included. For
- 130 MexEF-OprN upregulation, which is linked to fluoroquinolone AMR [21], we included function-altering
- 131 mutations or loss of coverage in mexS [80], the LysR family regulator mexT [81], and the global
- 132 regulator *mvaT* [82]. For MexXY upregulation, which is associated with aminoglycoside and

133	fluoroquinolone AMR, we included loss-of-coverage in two refined regions of mexZ [83, 84] and the
134	intergenic region (mexOZ) between mexZ and mexX [85, 86]. Additionally, functional gene loss variants
135	across the entire <i>P. aeruginosa</i> chromosome, identified via transposon insertion experiments [36, 38,
136	87], were included.
137	In addition to variants that confer AMR, mutations in essential AMR-conferring genes that cause

unusual antimicrobial susceptibility were included: efflux pumps mexAB [88, 89], mexXY [90], mexCD

[91] and mexEF [82, 92], and the ampC regulators ampP and ampG, which are required for high-level

140 *ampC* expression [51]. We also included additional targets for (meta)genome quality control and *P*.

141 *aeruginosa* speciation (*ecfX* [93]), and genes responsible for conferring a hypermutator phenotype

142 (*mutS*, *mutL* and *uvrD* [94]).

143 Global Dataset. To comprehensively capture geographic, genomic, and phenotypic diversity, we

collated a large and comprehensive *P. aeruginosa* isolate collection (*n*=1877) of all publicly available
strains with paired antimicrobial phenotype and genomic data [9, 20, 32, 54, 95-103] (Dataset 2, Table
S1). This dataset includes many antimicrobial-susceptible strains, which are essential for developing
and refining high-quality AMR databases [14, 104]. Isolates with minimum inhibitory concentration
(MIC) data were reclassified as sensitive, intermediate, or resistant using the CLSI M100S-Ed32:2022

149 guidelines.

150 **Validation Dataset.** To independently evaluate AMR software performance, we examined 102

151 phylogenetically diverse, analysis-naïve, clinical *P. aeruginosa* strains (Figures S1 and S2). Isolates were

obtained from people admitted to hospitals in Qld, Australia, with cystic fibrosis (CF; n=42),

bacteraemia (n=35), chronic obstructive pulmonary disease (COPD; n=21), bronchiectasis (n=1), ear

154 infection (*n*=1), ulcer (*n*=1), or urinary tract infection (*n*=1), between 2008 and 2020 (Table S2). Eighty-

155 four isolates have previously been genome-sequenced (NCBI BioProject PRJNA761496; GenBank

accessions NSXK00000000.1 and NSZK00000000.1) and some have previously undergone antimicrobial

susceptibility testing [105, 106]. For the current study, 18 additional COPD isolates (SCHI0038.S.1,

158 SCHI0050.S.3, SCHI0058.S.1, SCHI0058.S.2, SCHI0059.S.1, SCHI0064.S.1, SCHI0065.S.1, SCHI0068.S.3,

159	SCHI0070.S.1	, SCHI0070.S.1	, SCHI0084.S.1	, SCHI0098.S.1	, SCHI0103.S.1	, SCHI0107.S.1	, SCHI0109.S.1,

- 160 SCHI0109.S.2, SCHI0112.S.1, SCHI0112.S.2) were sequenced and appended to BioProject
- 161 PRJNA761496. Antimicrobial susceptibility profiles for 8 of 10 clinically-relevant antibiotics were
- 162 determined across the Validation Dataset (Table S2) using disc diffusions, following CLSI M100S-
- 163 Ed32:2022 guidelines. Meropenem and ciprofloxacin MICs were determined by ETEST (bioMérieux,
- 164 Murarrie, Australia) using sensitive, intermediate, and resistant MIC cut-offs of \leq 4, 8, and \geq 16 µg/mL
- 165 for meropenem, and ≤ 0.5 , 1, and $\geq 2 \mu g/mL$ for ciprofloxacin. PAO1 (Belgian Coordinated Collection of
- 166 Microorganisms [BCCM], Ghent University, Belgium) and LMG 6395 (BCCM) were included as
- 167 antimicrobial-susceptible controls.

168 Microbial genome-wide association study (mGWAS) and machine learning (ML) for AMR prediction.

169 To identify novel AMR variants, mGWAS [107] was performed on the Global *P. aeruginosa* Dataset

170 (*n*=1877 strains), with SNPs and indels identified using SPANDx v4.0.1 [108]. To increase the signal-to-

- 171 noise ratio, variants found in antimicrobial-sensitive isolates were penalised four-fold compared with
- 172 AMR strains due to a presumed large effect size [109]. The top 50 variants associated with each AMR
- 173 phenotype were assessed for their ability to improve phenotype prediction; those that improved
- 174 phenotype prediction were included in the AMR database. Additionally, a supervised ML approach was
- 175 performed using the Global Dataset and the AMR database as features for model creation.

176 **Comparative genomic analysis.** To identify additional novel AMR variants, we conducted a

177 comparative genomic analysis using SPANDx, with a focus on AMR strains that did not encode a known 178 AMR variant (i.e. false negatives). These strains were compared to their closest antimicrobial-sensitive 179 relative(s) as determined by the whole-genome phylogenetic analysis (Figure S1). SNPs and indels that 180 separated AMR from antimicrobial-sensitive strain/s were identified, annotated and investigated with 181 manual inspection to prioritise mutations in known AMR genes. Candidate variants were then tested 182 against the Global Dataset to determine whether they improved phenotype prediction. AMR variants 183 that increased balanced accuracy (bACC) were included in the database; those that did not alter, or 184 that decreased bACC, were discarded.

185 **AMR prediction analysis.** AMR prediction was performed using our *P. aeruginosa* AMR database

- 186 (v1.0), implemented in ARDaP [110]. ARDaP was chosen as it is the only AMR software that can detect
- 187 all mutation types (i.e. SNPs, indels, gene gain, gene loss, frameshift mutations, structural variants,
- and CNVs) [14]. ARDaP also has a built-in feature that automatically generates a clinician-friendly
- antimicrobial susceptibility summary report for each strain (Figure S3) to simplify in silico AMR
- 190 interpretation [14]. ARDaP performance was compared against four tools for AMR phenotype
- 191 prediction and/or AMR variant identification: abritAMR [111], RGI v5.1.0 and CARD v3.0.9 [11],
- 192 ResFinder v4.1 [10], and AMRFinderPlus v3.8.28 [112]. As abritAMR and AMRFinderPlus frequently
- report predicted AMR phenotypes to the antibiotic class level only, we chose to interpret AMR variant
- 194 presence for a given class as conferring AMR towards all antibiotics within that class. Importantly,
- 195 AMRFinderPlus is not intended for clinical phenotype prediction
- 196 (https://github.com/ncbi/amr/wiki/Interpreting-results#genotype-vs-phenotype) but has been
- 197 included as a benchmark for gene detection accuracy. For the purposes of software comparisons, gene
- identification by AMRFinderPlus was interpreted as conferring phenotypic resistance.
- 199 A variant scoring scheme has previously been described by Cortes-Lara and colleagues, which
- 200 employed a 0 (no effect) through 1 (EUCAST AMR) scale to predict in silico AMR profiles [102]. We
- 201 expanded upon this scheme by providing an automated weighted score for all AMR variants in our
- database that quantifies their contribution, positive or negative, towards AMR development (Dataset
- 203 1, 'Threshold' column); this score is recorded for each antibiotic on ARDaP's automatically generated
- clinician-friendly report (Figure S3), unlike the Cortes-Lara scheme, which requires manual scoring for
- 205 each antibiotic and strain [102]. Using our scoring system, variants known to cause AMR in isolation
- score as 100%, whereas AMR variants known to confer AMR in a stepwise manner (that is, only when
- in combination with other variant/s), or that only result in intermediate resistance, are given a lower
- score (e.g. 40-50%). This method accounts for both the additive nature of chromosomal mutations in
- 209 P. aeruginosa, and for the decreased AMR potential caused by loss of efflux pumps or essential

- 210 transcriptional regulators. Acquired AMR genes identified by Resfinder within ARDaP were considered
- to confer full AMR, i.e. are scored at 100% for the purposes of phenotype prediction.
- 212 Intermediate resistance prediction. The capacity of our AMR variant database to predict intermediate
- resistance phenotypes was examined against the Global Dataset using the following criteria:
- A true-positive prediction occurred when either: i) an AMR strain was classed as AMR, or ii) an
- 215 intermediate strain was identified as intermediate;
- A true-negative prediction occurred when an antimicrobial-sensitive strain was identified as
 antimicrobial sensitive;
- A false-positive prediction occurred when either: i) an antimicrobial-sensitive strain was
- 219 classed as intermediate or AMR, or ii) an intermediate strain was classed as AMR; and
- A false-negative prediction occurred when either: i) an intermediate strain was classed as
 antimicrobial-sensitive, or when an AMR strain was predicted to be antimicrobial-sensitive or
- 222 intermediate.
- 223 These rules provided the strictest evaluation criteria for the assessment of ARDaP's ability to identify
- intermediate strains. Only ARDaP's intermediate resistance prediction performance was assessed as
- abritAMR, AMRFinderPlus, CARD, and ResFinder all lack the capacity to identify intermediate
- 226 resistance.

227 AMR software predictive performance in *P. aeruginosa*. Due to its inability to predict AMR towards 228 individual antibiotics, and a very high rate of false-positive predictions in the Global Dataset, CARD was 229 deemed unsuitable for P. aeruginosa AMR analysis and was excluded from further assessment. For all 230 other tools, predictive performance was determined using bACC [113, 114], which averages sensitivity 231 [i.e. true positives/(true positives + false negatives)], and specificity [i.e. true negatives/(true negatives 232 + false positives)]. This metric was chosen as it accounts for dataset imbalance; that is, it minimises 233 over- or under- representation of antimicrobial-sensitive or AMR strains that may otherwise make 234 certain tools appear better or worse due to inherent dataset bias [8]. Additionally, we compared recall

- 235 (AMR) [true positives/(true positives + false negatives], precision (AMR) or positive predictive value
- 236 (PPV) [true positives/(true positives + false positives), recall (sensitivity) [true negatives/(true
- 237 negatives + false positives) and precision (sensitivity) or negative predictive value (NPV) [true
- 238 negatives/(true negatives + false negatives)] across all software tools.

239 Results

- 240 *P. aeruginosa* AMR variant identification and refinement. An extensive literature search was
- 241 undertaken to identify all known and putative chromosomal variants that lead to AMR in P.
- 242 *aeruginosa*. Among the 733 identified chromosomal AMR variants, 284 putative variants were
- 243 classified as 'natural variation' as they were common in both antimicrobial-sensitive and AMR strains
- in our Global Dataset, and therefore deemed unlikely to contribute to an AMR phenotype. Most of
- these naturally occurring variants had been previously reported as putatively causing AMR, with little
- to no functional investigation. Importantly, no functionally validated AMR driving variants were re-
- 247 classified as 'natural variation'. Next, using mGWAS and comparative genomic analyses of the Global
- 248 Dataset, we identified 75 previously unreported AMR variants associated with one or more AMR
- 249 phenotypes (Table 2). In total, we identified 736 chromosomal variants in known AMR loci (Dataset 2),
- of which 374 were associated with AMR and 284 were natural variation.
- 251 Predictive performance across Global Dataset. Although superior to CARD, abritAMR, AMRFinderPlus,
- and ResFinder still showed relatively poor bACCs for most antibiotics, with average bACCs of between
- 253 56 and 60%, well below ARDaP's average bACC of 85% (Figure 1A).
- 254 The best abritAMR, AMRFinderPlus, and ResFinder predictions were achieved for the aminoglycosides,
- with average bACCs of 75%, 75%, and 82%, respectively, although these rates were lower than
- ARDaP's average aminoglycoside bACC of 92%. abritAMR, AMRFinderPlus, and ResFinder AMR
- 257 prediction for all other antibiotics showed poor to very poor bACCs. AMRFinderPlus had a bACC of just
- 258 50% for the penicillins, cephalosporins, and colistin the same predictive capacity as a coin flip and
- had only a slightly better bACC for ciprofloxacin (58%), imipenem (58%), and meropenem (61%).

260	ResFinder also had a bACC of just 50% for cephalosporins and colistin, and performed worse for
261	carbapenems (average bACC of 50%) than AMRFinderPlus, although it was better for penicillins
262	(average bACC of 62%) and ciprofloxacin (bACC of 62%). abritAMR was the worst at predicting
263	penicillin phenotypes, with an average bACC of just 43%, worse than a coin flip; its performance was
264	otherwise identical to AMRFinderPlus. In contrast, ARDaP surpassed abritAMR, AMRFinderPlus, and
265	ResFinder across all 10 antibiotics, with bACCs ranging from 60% (colistin) to 94% (tobramycin) (Figure
266	1A).

- 267 Predictive performance across Validation Dataset. We next tested abritAMR, AMRFinderPlus, ARDaP,
- and ResFinder across the Validation Dataset of 102 Australian clinical *P. aeruginosa* strains (Table S2)
- to determine each software's performance in an analysis-naïve dataset. As no strains in the Validation
- 270 Dataset displayed colistin AMR, the bACC for this antibiotic could not be assessed. These strains
- otherwise exhibited similar AMR rates to the Global Dataset, ranging from 26% for meropenem to 58%
- 272 for piperacillin (Table S4).
- 273 Overall, ARDaP had high predictive accuracy (average bACC of 81%) across all antibiotics (Figure 1B),
- 274 vastly outperforming ResFinder (average bACC of 53%), abritAMR, and AMRFinderPlus (average bACC
- of 54% each). Notably, the ResFinder meropenem bACC, at just 43%, yielded worse performance than
 a coin flip.
- 277 Inclusion of the novel AMR variants identified in the Global Dataset. The inclusion of these markers
- increased Validation Dataset sensitivity by an average of 4% (range 0 to 27%) depending on antibiotic,
- 279 with the sensitivity of most antibiotics (meropenem, imipenem, ciprofloxacin, cefepime, and
- piperacillin/tazobactam) remaining unchanged. Amikacin increased the most (27%) due to the
- inclusion of a SNP in *rplB* (Gly138Ser), followed by tobramycin at 4%, and piperacillin and ceftazidime
 at 3% each."

ARDaP performance between the Global and Validation Datasets. Whilst ARDaP bACC between the
 datasets were broadly similar, there was a greater proportion of false-positive and false-negative

variants encoding AMR towards piperacillin (32% difference), tobramycin (24% difference), cefepime

- 286 (19% difference), amikacin (12% difference), and meropenem (9% difference) in the Validation
- 287 Dataset. In contrast, there was a greater proportion of false-positive and false-negative variants
- encoding amikacin AMR (5% difference) in the Global Dataset (Figure 1).
- 289 Comparative genomic analysis of Validation Dataset isolates that yielded false-negative
- aminoglycoside AMR predictions identified that many belonged to a single multilocus sequence type
- 291 (ST), ST801, also known as AUST-06. Among 23/24 aminoglycoside-AMR ST801 isolates, a clade-
- specific missense variant in elongation factor G (FusA1 S459F) was identified; this SNP was not
- 293 observed in other Global or Validation Dataset isolates. The remaining aminoglycoside-AMR ST801
- strain, SCHI0010.S.1, encoded AAC(6')-Ila, an aminoglycoside-modifying enzyme. Inclusion of FusA1
- 295 S459F into our AMR database significantly increased ARDaP bACCs for the Validation Dataset by an
- average 19% for both amikacin and tobramycin, raising them to 95% and 90%, respectively, with no
- 297 impact on Global Dataset bACC.
- 298 **Precision and recall among AMR software.** ARDaP demonstrated excellent precision and recall for
- 299 predicting antimicrobial-sensitive and AMR phenotypes, ranging from 73% (average AMR recall) to
- 300 96% (average sensitivity recall) (Figure 2A). In contrast, abritAMR ranged from 54% (average AMR
- 301 precision) to 62% (average sensitivity precision) (Figure 2B), AMRFinderPlus ranged from 54% (average
- 302 AMR precision) to 62% (average AMR recall) (Figure 2C), and ResFinder ranged from only 42% (average
- 303 AMR precision) to 68% (average sensitivity precision) (Figure 2D).
- 304 For colistin, abritAMR, AMRFinderPlus, and ResFinder all yielded AMR precision and recall values of
- 305 0%; in other words, none of these tools identified colistin AMR variants in strains exhibiting a colistin
- 306 AMR phenotype. In comparison, ARDaP identified colistin AMR strains with 21% recall and 100%
- 307 precision. Similarly, abritAMR, AMRFinderPlus, and ResFinder all failed to predict cefepime sensitivity
- 308 in any cefepime-sensitive strain (Figures 2B-2D), instead erroneously classing every strain as cefepime-
- 309 resistant, whereas ARDaP correctly identified cefepime-sensitive strains with 96% precision and 96%

- recall (Figure 2A). All three tools also failed to predict ceftazidime sensitivity. In addition, abritAMR
- and AMRFinderPlus failed to identify piperacillin sensitivity in any of the tested strains, and
- 312 AMRFinderPlus yielded failed to identify piperacillin/tazobactam sensitivity (Figures 2B and 2C).
- 313 **Predictive performance for intermediate resistance.** The inclusion of isolates with intermediate
- resistance reduced ARDaP bACCs by between 1 to 13% (6% average), depending on the antibiotic
- 315 (Table S5). Intermediate resistance inclusion was most detrimental to cefepime AMR prediction (-
- 316 13%), followed by imipenem (-8%), meropenem, ciprofloxacin and ceftazidime (-7%),
- 317 piperacillin/tazobactam and amikacin (-5%), piperacillin (-4%) and tobramycin (-1%). Colistin prediction
- 318 was unchanged as no intermediate category exists for this antibiotic.

319 Discussion

320	The increasing role of high-throughput sequencing in the clinic has driven the concomitant
321	development of bioinformatic tools for AMR variant detection and antimicrobial phenotype prediction
322	[115]. However, current gold standard AMR tools are limited in their accuracy and performance due to
323	their heavy focus on AMR gene gain rather than AMR-conferring chromosomal variants, and their
324	inability to detect the gamut of genetic mutations that can confer AMR (i.e. gene loss, indels, CNVs,
325	and structural variants) [14]. In addition, most tools have primarily focused on detection of AMR genes
326	rather than AMR phenotype prediction. These shortcomings become acutely evident when attempting
327	to predict AMR in pathogens with complex resistomes like <i>P. aeruginosa</i> [8].
328	To address this issue, we first constructed a comprehensive and accurate database of AMR variants
329	encoded by <i>P. aeruginosa</i> . Our database of 733 chromosomal AMR-conferring variants (Dataset 2)
330	comprises 374 previously identified AMR variants that we confirmed were significantly associated with
331	an AMR phenotype, along with 75 AMR variants identified in this study. A further 284 AMR variants
332	identified by us, and others, were classed as natural variants due to their non-significant association
333	with AMR strains (Table S3). These variants were included for two reasons: i) to allow ARDaP's
334	coverage algorithm to scan known AMR genes for novel, high-consequence mutations (e.g. frameshift
335	mutations in <i>oprD</i> that lead to carbapenem AMR) while avoiding natural variation that does not
336	impact function, ii) to substantially reduce the legwork involved in identifying putative novel AMR
337	variants using mGWAS or comparative genomics, and iii) to reduce the over-reporting of natural
338	variants as putatively AMR conferring. Our natural variant list also provides a valuable resource for
339	minimising erroneous AMR variant reporting in future <i>P. aeruginosa</i> AMR variant discovery studies.
340	Next, performance assessment of our ARDaP-compatible AMR database against the Global and
341	Validation Datasets showed that our tool outstripped the predictive performance of current 'gold
342	standard' AMR software across all 10 antibiotics, yielding average bACC of 85%, vs. just 56%, 58% and
343	60% for abriTAMR, AMRFinderPlus and ResFinder, respectively (Figure 1). This performance difference
344	is due to our chromosomal AMR variant database, which directly links genotypes with individual

345 antibiotic phenotypes, and provides weighted scores on variant contribution towards AMR

development (Dataset 1). Our findings concur with a recent study of 654 *P. aeruginosa* genomes,

347 which also found that CARD and ResFinder exhibited poor AMR prediction performance metrics across

all 11 tested anti-pseudomonal antibiotics [8].

349 Although still inferior to ARDaP, abritAMR, AMRFinderPlus, and ResFinder performed best when 350 predicting aminoglycoside phenotypes in the Global Dataset (Figure 1A), which is heavily populated 351 with American and European strains (Table S1). These tools performed substantially worse when 352 tested against the Australian Validation Dataset (Figure 1B), with the average aminoglycoside bACC 353 dropping by 16% for AMRFinderPlus and 26% for ResFinder. ARDaP's bACC also initially dropped by 354 18% for the aminoglycosides. Upon closer inspection, we found that this performance reduction was 355 predominantly due to false-negative calls among the ST801 isolates, a geographically restricted clone 356 that has only been reported in people with CF in Qld, Australia [116]. Inclusion of one novel fusA1 357 variant identified with comparative genomics in our AMR variant database restored ARDaP's 358 performance to bACC of 90% and 95% for amikacin and tobramycin, respectively. This performance 359 difference across isolate datasets can be attributed to two phenomena. The first is the predominance 360 of aminoglycoside-modifying enzymes in the Global (33%) but not Validation (8%) Datasets, reflecting 361 potential major differences in the geographic prevalence of these enzymes that requires further 362 exploration. The second is the enrichment of CF-derived isolates in the Validation Dataset, which 363 comprise 86% of the aminoglycoside AMR strains (Figure S1). These isolates have largely developed 364 aminoglycoside AMR via chromosomal mutation rather than aminoglycoside-modifying enzyme 365 acquisition; as such, abritAMR, AMRFinderPlus, and ResFinder exhibited poor aminogly coside AMR 366 predictive capacity due to their limited chromosomal AMR variant databases. These performance 367 differences highlight the need for including isolates from diverse sources, disease states, and locales to 368 provide the most relevant AMR prediction software benchmarking comparisons. Our results suggest 369 that abritAMR, AMRFinderPlus, and ResFinder are not useful for predicting aminoglycoside AMR from

370 CF-derived *P. aeruginosa*, particularly in the Australian context, although this finding requires further

371 exploration across larger, geographically diverse datasets.

372	Our findings revealed important weaknesses in abritAMR, AMRFinderPlus, and ResFinder when used
373	for phenotype prediction. All three tools yielded bACCs of just 50% for cephalosporin prediction,
374	abritAMR and AMRFinderPlus yielded a bACC of just 50% for piperacillin (Figures 1A and 1B), and
375	abritAMR performed worse than a coin flip for predicting piperacillin/tazobactam phenotypes, with a
376	bACC of just 35%. These cases of under-performance were largely attributed to sensitive isolates being
377	predicted as AMR (Figure 2). The inferior performance of abritAMR and AMRFinderPlus over ResFinder
378	was further exacerbated by their software design; for most anti-pseudomonal antibiotics, these tools
379	only predict phenotypes to the antibiotic class level. To facilitate direct software comparisons, AMR
380	identified for a given antibiotic class by abritAMR and AMRFinderPlus was extrapolated to all
381	antibiotics within that class, which likely led to higher imprecision or error due to differences in within-
382	class antibiotic spectrum of activity. For instance, the poor abritAMR piperacillin/tazobactam bACC
383	may be attributed to this tool only reporting ' eta -lactamase' presence; however, the impact of this eta -
384	lactamase on piperacillin/tazobactam efficacy is not explicitly reported due to insufficient granularity.
385	Based on our and other's [8] collective findings, we strongly discourage the use of abritAMR,
386	AMRFinderPlus, or ResFinder for in silico cephalosporin AMR prediction in P. aeruginosa as none of
387	these tools are currently capable of accurately differentiating sensitive from AMR strains for these
388	antibiotics. Further, abritAMR and AMRFinderPlus should not be used to predict penicillin
389	susceptibility phenotypes in <i>P. aeruginosa</i> due to their insufficient resolution.
390	Colistin prediction proved the most challenging of the 10 tested antibiotics, yielding bACCs of 50%
391	with abriTAMR, AMRFinderPlus, and ResFinder, and 60% with ARDaP. ARDaP the only tool able to
392	correctly predict some colistin AMR strains; the other three tools erroneously classified all P.
393	aeruginosa strains as colistin-sensitive (Figures 2B and 2C). Accurate colistin prediction may have been
394	hampered by the purported unreliability of gradient diffusion methods (e.g. disc diffusions, ETESTS) to
395	accurately measure colistin breakpoints due to poor antibiotic diffusion and Mueller-Hinton agar

396	manufacturer differences [117, 118]. Our study has identified a major gap in understanding the basis
397	of colistin AMR, and underscores the need for much more work in this area, especially given the
398	increasing use of inhaled colistin in treatment-refractory, multidrug-resistant P. aeruginosa infections
399	[119, 120].

400 Loss-of-function mutations affecting the specialised porin, OprD, are the most common cause of 401 carbapenem AMR in *P. aeruginosa*, particularly in clinical isolates [9]. Although oprD is notoriously 402 hypervariable [121], ARDaP's ability to accurately identify functional OprD loss accounted for its high 403 carbapenem predictive accuracy (average bACC of 89% vs. just 61% for AMRFinderPlus and 52% for 404 ResFinder). This outcome highlights the complex nature of the *P. aeruginosa* resistome, the necessity 405 of AMR variant curation efforts, the value of AMR prediction tools that can accurately detect the 406 spectrum of chromosomal variants, and the value of species-specific AMR variant databases to achieve 407 the most accurate AMR predictions. 408 Mutations leading to chromosomal cephalosporinase (ampC) overexpression are an important cause 409 of β -lactam AMR [15, 122]. To predict *ampC* upregulation, our database includes function-altering

mutations in genes known to directly or indirectly regulate *ampC*. These chromosomally-encoded
variants, alongside acquired cephalosporinases, accounted for the high average ARDaP bACC observed

for the cephalosporins (84% vs. just 50% with abritAMR, AMRFinderPlus, and ResFinder; Figure 1). The

413 prominence of *ampC* over-expression-associated determinants provides further support that this

414 mechanism is a major cause of acquired cephalosporin AMR, particularly in clinical *P. aeruginosa*

415 isolates [122, 123]. In support of this hypothesis, Khaledi and colleagues demonstrated a considerably

416 higher bACC for ceftazidime AMR prediction when using both transcriptomic and genomic data (82%)

417 compared with just genomic data (67%) [9]. Genomics alone cannot currently identify all instances of

418 *ampC* over-expression, either because up-regulation is the result of an epigenic change, or the

419 mutation remains cryptic due to an incomplete understanding of *ampC* regulatory mechanisms.

420 Indeed, a review of intrinsic β-lactamases by Juan and colleagues details the complexity of *ampC*

421 expression and its intricate regulation, along with the challenge of corresponding elevated β-

lactamase MICs driven by *ampC* upregulation to clinical AMR breakpoints [124]. Using a combination
of genomic and transcriptomic data will likely lead to further improvements in AMR prediction for
most antibiotics [9, 122].

425 Predicting intermediate resistance is exceedingly difficult from genomic data alone, even with complex 426 machine learning algorithms that combine transcriptomic and genomic data [9]. We also encountered 427 difficulties in predicting intermediate resistance, with the inclusion of intermediate strains dropping 428 bACCs by up to 13% (Table S5). Possible explanations include the need to understand the contribution 429 of stepwise variants in conferring decreased antibiotic susceptibility [15, 67, 125], subtle and rapidly 430 reversible gene expression alterations [9] caused by methylation [126] or dynamic environmental 431 stimuli, and undetected strain mixtures. Further refinement of our ARDaP-compatible database, such 432 as capacity to analyse RNA-seq data, will continue to improve this critical yet understudied area. 433 Nevertheless, the pioneering capacity of ARDaP to predict intermediate resistance, including stepwise 434 mutations that lower the barrier to full AMR development, and to differentiate strain mixtures in 435 metagenomic data, has important implications for detecting emerging AMR in *P. aeruginosa* and 436 informing earlier treatment shifts [14]. 437 Errors introduced during sample collection, metadata curation, specimen processing, or sequencing 438 may be partially responsible for our inability to predict AMR with a 100% bACC for any antibiotic. For 439 example, 11 strains in the Khaledi et al. dataset [9] possessed variants known to confer ceftazidime 440 AMR (e.g. *bla*_{VIM-[2,4,47]}, *bla*_{QXA-2}, *bla*_{GE5-[1,5]}) yet were reported as ceftazidime-sensitive, and 22 strains in 441 the Kos et al. dataset were amikacin-sensitive, yet possessed the aminoglycoside-modifying enzyme 442 gene *aac(6')-lb-cr*, known to cause amikacin AMR and reduced ciprofloxacin susceptibility [127]. Due

to the presence of these known AMR variants, all tools identified these strains as AMR, contributing to imperfect bACC (Figure 1) and poor precision (Figure 2) for amikacin and ceftazidime. As we did not have access to these strains, it was not possible to retest their AMR phenotypes or to repeat genome sequencing; however, we hypothesise that these strains would generate different results upon phenotypic retesting or re-sequencing. Alternatively, these AMR variants may be present but

448 functionally or transcriptionally inactive, resulting in false-positive predictions for these isolates that

449 must be factored into future AMR prediction estimates.

450 We recognise several study limitations. First, some false-positive predictions were identified across all 451 antibiotic classes with our ARDaP-compatible database; however, these rates were significantly lower 452 than those reported by other software (Figure 1). Whilst not ideal, we chose to retain a small number 453 of AMR variants that result in low-frequency false-positive predictions as: i) some strains may have 454 reverted to a sensitive phenotype, despite encoding a known AMR variant; and ii) we included 455 phenotypic data generated by others, which may harbour inaccuracies. Functional profiling will be 456 essential to fully understand the contribution of each of these variants in conferring AMR. Second, 457 although we aimed for a phylogenetically diverse Validation Dataset (Figure S1, S2), only isolates from Queensland, Australia, were included in this dataset, limiting geographic and genetic representation. 458 459 Despite this shortcoming, the Validation Dataset proved extremely useful for identifying AMR variant 460 database deficits across all three AMR tools, particularly those variants encoding AMR towards the 461 aminoglycosides, piperacillin, cefepime, and meropenem, highlighting clear areas of need for future 462 research efforts. Third, due to cost constraints, we only performed ciprofloxacin and meropenem 463 ETESTs for the Validation Dataset isolates, with disc diffusions used for the remaining eight antibiotics, 464 a less robust methodology that may have led to some minor discrepancies in antimicrobial phenotype 465 assignments. Fourth, we did not test out ARDaP's capacity to identify *P. aeruginosa* AMR variants from 466 simulated and real metagenomic datasets and strain mixtures for this study as we have proven this 467 capacity elsewhere [14, 106] nor were we able to compare software performance against ARESdb 468 [128] due to the proprietary nature of this database. Finally, our study would have benefitted from the 469 inclusion of transcriptomic data [9] to identify additional novel variants associated with AMR. Although 470 our understanding of the molecular mechanisms of AMR in *P. aeruginosa* is improving rapidly in the 471 genomics era, false-negative predictions still occur across all antibiotic classes. Using ARDaP, such 472 false-negative strains can now be rapidly identified and targeted for future functional work to pinpoint 473 novel AMR variants and mechanisms.

474 Declarations

475	Ethics approval and consent to participate. Clinical specimen collection was approved by The Prince
476	Charles Hospital (HREC/13/QPCH/127 and HREC/2019/QPCH/48013) and Royal Brisbane and Women's
477	Hospital (DA: jl) Human Research Ethics Committees. Participants with CF or COPD provided written
478	consent; a waiver of informed consent was approved for other specimens due to a low-to-negligible
479	risk assessment.
480	Consent for publication. Not applicable.
481	Availability of data and materials. The datasets supporting the conclusions of this article are available
482	in the NCBI GenBank (references NSXK0000000.1 and NSZK0000000.1) and Sequence Read Archive
483	database via BioProject accession PRJNA761496 (Validation Dataset), and BioProject accessions
484	PRJEB15036, PRJEB21341, PRJEB29539, PRJEB14771, PRJNA297679, PRJNA317143, PRJNA526797,
485	PRJNA264310, PRJNA388357, PRJNA793523, PRJEB40140 and PRJNA532924 (Global Dataset). The <i>P</i> .
486	aeruginosa AMR database constructed for this study is freely available at:
487	https://github.com/dsarov/ARDaP/tree/master/Databases/Pseudomonas_aeruginosa_pao1. The
488	ARDaP software is freely available at: <u>https://github.com/dsarov/ARDaP</u> . All code used in this
489	manuscript is available at https://github.com/dsarov/P aeruginosa ARDaP manuscript.
490	Competing interests. The authors declare that they have no competing interests.
491	Funding. This work was supported by Advance Queensland [AQIRF0362018 to D.S.S., AQRF13016-
492	17RD2 to E.P.P.]; the Wishlist Sunshine Coast Health Foundation [2019-14 to T.B., E.P.P., D.S.S.]; and
493	the National Health and Medical Research Council [GNT455919 to S.C.B.]. The funders had no role in
494	study design, data acquisition, analysis, interpretation, writing, or manuscript submission.
495	Authors' contributions. DEM drafted the initial manuscript, compiled the original P. aeruginosa AMR
496	variant database, performed data analyses and laboratory work, and assisted with ARDaP software
497	refinement; TB provided chronic obstructive pulmonary disease respiratory specimens that were used
498	to retrieve <i>P. aeruginosa</i> isolates, assisted with obtaining ethics approvals for sputum and bronchial
	21

499 washing collection, and obtained study funding; SCB provided CF sputa that were used to retrie	etrieve P.
--	------------

- 500 aeruginosa isolates, and obtained ethics approval for sputum collection; KM provided bloodstream P.
- 501 *aeruginosa* isolates, and obtained ethics approval for blood collection; EPP assisted with study
- 502 conception, obtaining and overseeing ethics approvals, manuscript preparation, data analyses and
- 503 laboratory work, provided student supervision, obtained study funding, and assisted with curation of
- 504 the natural variant database; and DSS conceived and led the study, wrote the ARDaP software, refined
- 505 the *P. aeruginosa* AMR variant database, assisted with manuscript preparation, data analyses and
- 506 laboratory work, provided student supervision, and obtained study funding. All authors read and
- 507 approved of the final manuscript.
- 508 Acknowledgements. We wish to thank Jane Neill (Sunshine Coast Hospital and Health Service,
- 509 Sunshine Coast University Hospital) for providing the chronic obstructive pulmonary samples used in
- 510 this study, and Kay Ramsay (University of Queensland) and Tamieka Fraser (University of the Sunshine
- 511 Coast) for laboratory support.

512 References

F10	1	Manager C. Midigi A. Causas E. Dianda C. Destavial antibiatic registerios. The most without
513	1.	Mancuso G, Midiri A, Gerace E, Biondo C: Bacterial antibiotic resistance: The most critical
514	2	pathogens. Pathogens (Basel, Switzerland) 2021, 10 (10):1310.
515	2.	Bassetti M, Merelli M, Temperoni C, Astilean A: New antibiotics for bad bugs: where are we?
516		Annals of Clinical Microbiology and Antimicrobials 2013, 12 (1):22.
517	3.	Alanis AJ: Resistance to antibiotics: are we in the post-antibiotic era? Archives of Medical
518		Research 2005, 36 (6):697-705.
519	4.	Antimicrobial resistance: Tackling a crisis for the health and wealth of nations
520	5.	G. B. D. Antimicrobial Resistance Collaborators: Global mortality associated with 33 bacterial
521		pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet
522		2022, 400 (10369):2221-2248.
523	6.	Denissen J, Reyneke B, Waso-Reyneke M, Havenga B, Barnard T, Khan S, Khan W: Prevalence
524		of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired
525		infection and risk to human health. Int J Hyg Environ Health 2022, 244:114006.
526	7.	Haenni M, Hocquet D, Ponsin C, Cholley P, Guyeux C, Madec JY, Bertrand X: Population
527		structure and antimicrobial susceptibility of Pseudomonas aeruginosa from animal
528		infections in France. BMC Vet Res 2015, 11 :9.
529	8.	Mahfouz N, Ferreira I, Beisken S, von Haeseler A, Posch AE: Large-scale assessment of
530	•	antimicrobial resistance marker databases for genetic phenotype prediction: a systematic
531		review. Journal of Antimicrobial Chemotherapy 2020, 75 (11):3099-3108.
532	9.	Khaledi A, Weimann A, Schniederjans M, Asgari E, Kuo TH, Oliver A, Cabot G, Kola A, Gastmeier
533	5.	P, Hogardt M <i>et al</i> : Predicting antimicrobial resistance in <i>Pseudomonas aeruginosa</i> with
533 534		machine learning-enabled molecular diagnostics. EMBO Mol Med 2020, 12 (3):e10264.
535	10	
	10.	Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,
536		Rebelo AR, Florensa AF <i>et al</i> : ResFinder 4.0 for predictions of phenotypes from genotypes .
537		Journal of Antimicrobial Chemotherapy 2020, 75 (12):3491-3500.
538	11.	Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen A-
539		LV, Cheng AA, Liu S et al: CARD 2020: antibiotic resistome surveillance with the
540		comprehensive antibiotic resistance database. Nucleic Acids Research 2019, 48(D1):D517-
541		D525
542	12.	Hunt M, Mather AE, Sanchez-Buso L, Page AJ, Parkhill J, Keane JA, Harris SR: ARIBA: Rapid
543		antimicrobial resistance genotyping directly from sequencing reads. Microbial genomics
544		2017, 3 (10):e000131.
545	13.	Zankari E, Allesoe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM: PointFinder: A novel web
546		tool for WGS-based detection of antimicrobial resistance associated with chromosomal
547		point mutations in bacterial pathogens. Journal of Antimicrobial Chemotherapy 2017,
548		72 (10):2764-2768.
549	14.	Madden DE, Webb JR, Steinig EJ, Currie BJ, Price EP, Sarovich DS: Taking the next-gen step:
550		Comprehensive antimicrobial resistance detection from Burkholderia pseudomallei.
551		EBioMedicine 2021, 63 :103152.
552	15.	Lister PD, Wolter DJ, Hanson ND: Antibacterial-resistant <i>Pseudomonas aeruginosa:</i> Clinical
553		impact and complex regulation of chromosomally encoded resistance mechanisms. Clinical
554		Microbiology Reviews 2009, 22 (4):582-610.
555	16.	Pesesky MW, Hussain T, Wallace M, Patel S, Andleeb S, Burnham CD, Dantas G: Evaluation of
556		machine learning and rules-based approaches for predicting antimicrobial resistance profiles
557		in Gram-negative Bacilli from whole genome sequence data. Frontiers in microbiology 2016,
558		7 :1887.
559	17.	Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, Rolain JM: ARG-
560	±7.	ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial
561		genomes. Antimicrobial agents and chemotherapy 2014, 58 (1):212-220.
201		Benemes. Antimicrobial agents and chemotherapy 2014, 30(1).212-220.

562	18.	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle
563		WO, Kowalik DJ, Lagrou M <i>et al</i> : Complete genome sequence of <i>Pseudomonas aeruginosa</i>
564		PAO1, an opportunistic pathogen. Nature 2000, 406(6799):959-964.
565	19.	Lopez-Causape C, Cabot G, Del Barrio-Tofino E, Oliver A: The versatile mutational resistome of
566		Pseudomonas aeruginosa. Frontiers in microbiology 2018, 9 :685.
567	20.	Kos VN, Deraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, Gardner H: The
568		resistome of <i>Pseudomonas aeruginosa</i> in relationship to phenotypic susceptibility.
569		Antimicrobial agents and chemotherapy 2015, 59 (1):427-436.
570	21.	Poole K: Pseudomonas aeruginosa: Resistance to the max . Frontiers in microbiology 2011,
571		2 :65-65.
572	22.	Richardot C, Plesiat P, Fournier D, Monlezun L, Broutin I, Llanes C: Carbapenem resistance in
573		cystic fibrosis strains of <i>Pseudomonas aeruginosa</i> as a result of amino acid substitutions in
574		porin OprD . International journal of antimicrobial agents 2015, 45 (5):529-532.
575	23.	Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N:
576	23.	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in <i>Pseudomonas</i>
577		<i>aeruginosa</i> isolates from cystic fibrosis patients. Antimicrobial agents and chemotherapy
578		2010, 54 (5):2219-2224.
579	24.	Lister PD, Wolter DJ, Hanson ND: Antibacterial-resistant <i>Pseudomonas aeruginosa:</i> Clinical
580	24.	impact and complex regulation of chromosomally encoded resistance mechanisms. <i>Clinical</i>
581		Microbiology Reviews 2009, 22 (4):582-610.
582	25.	Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,
583	25.	Rebelo AR, Florensa AF <i>et al</i> : ResFinder 4.0 for predictions of phenotypes from genotypes . J
585 584		Antimicrob Chemother 2020, 75 (12):3491-3500.
585	26.	Heffernan AJ, Sime FB, Sarovich DS, Neely M, Guerra-Valero Y, Naicker S, Cottrell K, Harris P,
586	20.	Andrews KT, Ellwood D <i>et al</i> : Pharmacodynamic evaluation of plasma and epithelial lining
587		fluid exposures of amikacin against <i>Pseudomonas aeruginosa</i> in a dynamic <i>in vitro</i> hollow-
588		fiber infection model. Antimicrobial agents and chemotherapy 2020, 64 (9).
589	27.	Lau CH, Krahn T, Gilmour C, Mullen E, Poole K: AmgRS-mediated envelope stress-inducible
590	27.	expression of the <i>mexXY</i> multidrug efflux operon of <i>Pseudomonas aeruginosa</i> .
591		MicrobiologyOpen 2015, 4 (1):121-135.
592	28.	Bolard A, Plésiat P, Jeannot K: Mutations in gene <i>fusA1</i> as a novel mechanism of
593	20.	aminoglycoside resistance in clinical strains of <i>Pseudomonas aeruginosa</i> . Antimicrobial
594		agents and chemotherapy 2018, 62 (2).
595	29.	Wardell SJT, Rehman A, Martin LW, Winstanley C, Patrick WM, Lamont IL: A large-scale whole-
596	23.	genome comparison shows that experimental evolution in response to antibiotics predicts
597		changes in naturally evolved clinical <i>Pseudomonas aeruginosa</i> . Antimicrobial agents and
598		chemotherapy 2019.
599	30.	López-Causapé C, Sommer LM, Cabot G, Rubio R, Ocampo-Sosa AA, Johansen HK, Figuerola J,
600	00.	Cantón R, Kidd TJ, Molin S <i>et al</i> : Evolution of the <i>Pseudomonas aeruginosa</i> mutational
601		resistome in an international cystic fibrosis clone. Sci Rep 2017, 7(1):5555.
602	31.	Lopez-Causape C, Rubio R, Cabot G, Oliver A: Evolution of the <i>Pseudomonas aeruginosa</i>
603	51.	aminoglycoside mutational resistome <i>in vitro</i> and in the cystic fibrosis setting. Antimicrobial
604		agents and chemotherapy 2018, 62 (4).
605	32.	Sherrard LJ, Tai AS, Wee BA, Ramsay KA, Kidd TJ, Ben Zakour NL, Whiley DM, Beatson SA, Bell
606	52.	SC: Within-host whole genome analysis of an antibiotic resistant <i>Pseudomonas aeruginosa</i>
607		strain sub-type in cystic fibrosis. <i>PLoS One</i> 2017, 12 (3):e0172179.
608	33.	Feng Y, Jonker MJ, Moustakas I, Brul S, Ter Kuile BH: Dynamics of mutations during
609	55.	development of resistance by <i>Pseudomonas aeruginosa</i> against five antibiotics.
610		Antimicrobial agents and chemotherapy 2016, 60 (7):4229-4236.
611	34.	Khaledi A, Weimann A, Schniederjans M, Asgari E, Kuo T-H, Oliver A, Cabot G, Kola A,
612	<u>ст.</u>	Gastmeier P, Hogardt M <i>et al</i> : Predicting antimicrobial resistance in <i>Pseudomonas</i>
613		aeruginosa with machine learning-enabled molecular diagnostics. EMBO molecular medicine
614		2020, 12 (3):e10264-e10264.

615	35.	Sanz-Garcia F, Hernando-Amado S, Martinez JL: Mutational evolution of Pseudomonas
616		aeruginosa resistance to ribosome-targeting antibiotics. Front Genet 2018, 9:451.
617	36.	Schurek KN, Marr AK, Taylor PK, Wiegand I, Semenec L, Khaira BK, Hancock RE: Novel genetic
618		determinants of low-level aminoglycoside resistance in <i>Pseudomonas aeruginosa</i> .
619		Antimicrobial agents and chemotherapy 2008, 52 (12):4213-4219.
620	37.	Sun E, Gill EE, Falsafi R, Yeung A, Liu S, Hancock REW: Broad-spectrum adaptive antibiotic
621		resistance associated with Pseudomonas aeruginosa mucin-dependent surfing motility.
622		Antimicrobial agents and chemotherapy 2018, 62 (9).
623	38.	Dotsch A, Becker T, Pommerenke C, Magnowska Z, Jansch L, Haussler S: Genomewide
624		identification of genetic determinants of antimicrobial drug resistance in Pseudomonas
625		aeruginosa . Antimicrobial agents and chemotherapy 2009, 53 (6):2522-2531.
626	39.	Berrazeg M, Jeannot K, Ntsogo Enguene VY, Broutin I, Loeffert S, Fournier D, Plesiat P:
627		Mutations in beta-Lactamase <i>ampC</i> increase resistance of <i>Pseudomonas aeruginosa</i> isolates
628		to antipseudomonal cephalosporins. Antimicrobial agents and chemotherapy 2015,
629		59 (10):6248-6255.
630	40.	Colque CA, Albarracín Orio AG, Feliziani S, Marvig RL, Tobares AR, Johansen HK, Molin S,
631		Smania AM: Hypermutator Pseudomonas aeruginosa exploits multiple genetic pathways to
632		develop multidrug resistance during long-term infections in the airways of cystic fibrosis
633		patients . Antimicrobial agents and chemotherapy 2020, 64 (5).
634	41.	Slater CL, Winogrodzki J, Fraile-Ribot PA, Oliver A, Khajehpour M, Mark BL: Adding insult to
635		injury: Mechanistic basis for how AmpC mutations allow Pseudomonas aeruginosa to
636		accelerate cephalosporin hydrolysis and evade avibactam. Antimicrobial agents and
637		chemotherapy 2020, 64 (9).
638	42.	Fernandez-Esgueva M, Lopez-Calleja AI, Mulet X, Fraile-Ribot PA, Cabot G, Huarte R, Rezusta A,
639		Oliver A: Characterization of AmpC beta-lactamase mutations of extensively drug-resistant
640		Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during
641		therapy. Enferm Infecc Microbiol Clin (Engl Ed) 2020, 38 (10):474-478.
642	43.	Moya B, Dotsch A, Juan C, Blazquez J, Zamorano L, Haussler S, Oliver A: Beta-lactam resistance
643		response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog
644		2009, 5 (3):e1000353.
645	44.	Zamorano L, Reeve TM, Deng L, Juan C, Moya B, Cabot G, Vocadlo DJ, Mark BL, Oliver A: NagZ
646		inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4
647		mutations, in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 2010,
648		54 (9):3557-3563.
649	45.	Barbosa C, Gregg KS, Woods RJ: Variants in <i>ampD</i> and <i>dacB</i> lead to in vivo resistance
650		evolution of <i>Pseudomonas aeruginosa</i> within the central nervous system. <i>Journal of</i>
651		Antimicrobial Chemotherapy 2020, 75 (11):3405-3408.
652	46.	Langaee TY, Gagnon L, Huletsky A: Inactivation of the ampD gene in Pseudomonas
653		<i>aeruginosa</i> leads to moderate-basal-level and hyperinducible AmpC beta-lacta mase
654		expression. Antimicrobial agents and chemotherapy 2000, 44(3):583-589.
655	47.	Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, Oliver A: Molecular mechanisms of beta-
656		lactam resistance mediated by AmpC hyperproduction in <i>Pseudomonas aeruginosa</i> clinical
657		strains. Antimicrobial agents and chemotherapy 2005, 49 (11):4733-4738.
658	48.	Bagge N, Ciofu O, Hentzer M, Campbell JI, Givskov M, Hoiby N: Constitutive high expression of
659		chromosomal beta-lactamase in <i>Pseudomonas aeruginosa</i> caused by a new insertion
660		sequence (IS1669) located in ampD. Antimicrobial agents and chemotherapy 2002,
661		46 (11):3406-3411.
662	49.	Quale J, Bratu S, Gupta J, Landman D: I nterplay of efflux system, ampC, and oprD expression
663		in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrobial agents
664		and chemotherapy 2006, 50 (5):1633-1641.
665	50.	Tsutsumi Y, Tomita H, Tanimoto K: Identification of novel genes responsible for
666		overexpression of ampC in Pseudomonas aeruginosa PAO1. Antimicrobial agents and
667		chemotherapy 2013, 57 (12):5987-5993.

668	51.	Kong KF, Aguila A, Schneper L, Mathee K: Pseudomonas aeruginosa β-lactamase induction
669	_	requires two permeases, AmpG and AmpP. BMC microbiology 2010, 10:328.
670	52.	Cabot G, Lopez-Causape C, Ocampo-Sosa AA, Sommer LM, Dominguez MA, Zamorano L, Juan
671		C, Tubau F, Rodriguez C, Moya B et al: Deciphering the resistome of the widespread
672		Pseudomonas aeruginosa sequence type 175 international high-risk clone through whole-
673		genome sequencing. Antimicrob Agents Chemother 2016, 60(12):7415-7423.
674	53.	Clark ST, Sinha U, Zhang Y, Wang PW, Donaldson SL, Coburn B, Waters VJ, Yau YCW, Tullis DE,
675		Guttman DS et al: Penicillin-binding protein 3 is a common adaptive target among
676		Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with beta-
677		lactams. International journal of antimicrobial agents 2019, 53 (5):620-628.
678	54.	Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM,
679		Sorlí L, Tubau F, Gómez-Zorrilla S et al: Genomics and susceptibility profiles of extensively
680		drug-resistant Pseudomonas aeruginosa isolates from Spain. Antimicrobial agents and
681		chemotherapy 2017, 61 (11).
682	55.	Sherrard LJ, Wee BA, Duplancic C, Ramsay KA, Dave KA, Ballard E, Wainwright CE, Grimwood K,
683		Sidjabat HE, Whiley DM et al: Emergence and impact of oprD mutations in Pseudomonas
684		aeruginosa strains in cystic fibrosis . Journal of cystic fibrosis : official journal of the European
685		Cystic Fibrosis Society 2021.
686	56.	Livermore DM: Interplay of impermeability and chromosomal beta-lactamase activity in
687		i mipenem-resistant Pseudomonas aeruginosa . Antimicrobial agents and chemotherapy 1992,
688		36 (9):2046-2048.
689	57.	Ocampo-Sosa AA, Cabot G, Rodriguez C, Roman E, Tubau F, Macia MD, Moya B, Zamorano L,
690		Suarez C, Pena C <i>et al</i> : Alterations of OprD in carbapenem-intermediate and -susceptible
691		strains of <i>Pseudomonas aeruginosa</i> isolated from patients with bacteremia in a Spanish
692		multicenter study. Antimicrobial agents and chemotherapy 2012, 56 (4):1703-1713.
693	58.	Fraile-Ribot PA, Mulet X, Cabot G, Del Barrio-Tofino E, Juan C, Perez JL, Oliver A: In vivo
694		emergence of resistance to novel cephalosporin-beta-lactamase inhibitor combinations
695		through the duplication of amino acid D149 from OXA-2 beta-lactamase (OXA-539) in
696		sequence type 235 <i>Pseudomonas aeruginosa</i> . Antimicrobial agents and chemotherapy 2017,
697		61 (9).
698	59.	Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, Haussler S, Oliver A:
699		Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple
700		mutations leading to overexpression and structural modification of AmpC. Antimicrobial
701		agents and chemotherapy 2014, 58 (6):3091-3099.
702	60.	Perron K, Caille O, Rossier C, Van Delden C, Dumas JL, Kohler T: CzcR-CzcS, a two-component
703		system involved in heavy metal and carbapenem resistance in <i>Pseudomonas aeruginosa</i> . J
704		Biol Chem 2004, 279 (10):8761-8768.
705	61.	Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ: Mutations in GyrA, ParC, MexR and
706		NfxB in clinical isolates of Pseudomonas aeruginosa. International journal of antimicrobial
707		agents 2003, 21 (5):409-413.
708	62.	Lee JK, Lee YS, Park YK, Kim BS: Alterations in the GyrA and GyrB subunits of topoisomerase II
709		and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical
710		i solates of Pseudomonas aeruginosa . International journal of antimicrobial agents 2005,
711		25 (4):290-295.
712	63.	Bruchmann S, Dötsch A, Nouri B, Chaberny IF, Häussler S: Quantitative contributions of target
713		alteration and decreased drug accumulation to <i>Pseudomonas aeruginosa</i> fluoroquinolone
714		resistance. Antimicrobial agents and chemotherapy 2013, 57(3):1361-1368.
715	64.	Jalal S, Wretlind B: Mechanisms of quinolone resistance in clinical strains of <i>Pseudomonas</i>
716		aeruginosa . Microbial drug resistance (Larchmont, NY) 1998, 4 (4):257-261.
717	65.	Alyaseen SA, Piper KE, Rouse MS, Steckelberg JM, Patel R: Selection of cross-resistance
718		following exposure of <i>Pseudomonas aeruginosa</i> clinical isolates to ciprofloxacin or cefepime.
719		Antimicrobial agents and chemotherapy 2005, 49 (6):2543-2545.

720	66.	Akasaka T, Tanaka M, Yamaguchi A, Sato K: Type II topoisomerase mutations in
721		fluoroquinolone-resistant clinical strains of <i>Pseudomonas aeruginosa</i> isolated in 1998 and
722		1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrobial
723		agents and chemotherapy 2001, 45 (8):2263-2268.
724	67.	Rehman A, Jeukens J, Levesque RC, Lamont IL: Gene-gene interactions dictate ciprofloxacin
725		resistance in <i>Pseudomonas aeruginosa</i> and facilitate prediction of resistance phenotype
726		from genome sequence data. Antimicrobial agents and chemotherapy 2021, 65(7):e0269620.
727	68.	Chilam J, Argimon S, Limas MT, Masim ML, Gayeta JM, Lagrada ML, Olorosa AM, Cohen V,
728		Hernandez LT, Jeffrey B et al: Genomic surveillance of Pseudomonas aeruginosa in the
729		Philippines, 2013-2014. Western Pac Surveill Response J 2021, 12(2):4-18.
730	69.	Lee JY, Ko KS: Mutations and expression of PmrAB and PhoPQ related with colistin resistance
731		in Pseudomonas aeruginosa clinical isolates. Diagn Microbiol Infect Dis 2014, 78(3):271-276.
732	70.	Moskowitz SM, Ernst RK, Miller SI: PmrAB, a two-component regulatory system of
733		Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and
734		addition of aminoarabinose to lipid A. J Bacteriol 2004, 186(2):575-579.
735	71.	Abraham N, Kwon DH: A single amino acid substitution in PmrB is associated with polymyxin
736		B resistance in clinical isolate of Pseudomonas aeruginosa. FEMS Microbiol Lett 2009,
737		298 (2):249-254.
738	72.	Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, Selgrade SE, Miller SI,
739		Denton M, Conway SP <i>et al</i> : PmrB mutations promote polymyxin resistance of <i>Pseudomonas</i>
740		aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrobial agents and
741		chemotherapy 2012, 56 (2):1019-1030.
742	73.	Owusu-Anim D, Kwon DH: Differential role of two-component regulatory systems (phoPQ
743	, 0,	and <i>pmrAB</i>) in polymyxin B susceptibility of <i>Pseudomonas aeruginosa</i> . Advances in
744		microbiology 2012, 2 (1).
745	74.	Choi MJ, Ko KS: Mutant prevention concentrations of colistin for Acinetobacter baumannii,
746	/ -1.	Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates. Journal of
747		Antimicrobial Chemotherapy 2014, 69 (1):275-277.
748	75.	Saito K, Akama H, Yoshihara E, Nakae T: Mutations affecting DNA-binding activity of the
749	75.	MexR repressor of mexR-mexA-mexB-oprM operon expression. J Bacteriol 2003,
750		185 (20):6195-6198.
751	76.	Vaez H, Safaei HG, Faghri J: The emergence of multidrug-resistant clone ST664 Pseudomonas
752	,	aeruginosa in a referral burn hospital, Isfahan, Iran. Burns Trauma 2017, 5:27.
753	77.	Braz VS, Furlan JP, Fernandes AF, Stehling EG: Mutations in NalC induce MexAB-OprM
754	,,,,	overexpression resulting in high level of aztreonam resistance in environmental isolates of
755		Pseudomonas aeruginosa . FEMS Microbiol Lett 2016, 363 (16).
756	78.	Suresh M, Nithya N, Jayasree PR, Vimal KP, Manish Kumar PR: Mutational analyses of
757	70.	regulatory genes, mexR, nalC, nalD and mexZ of mexAB-oprM and mexXY operons, in efflux
758		pump hyperexpressing multidrug-resistant clinical isolates of <i>Pseudomonas aeruginosa</i> .
759		World journal of microbiology & biotechnology 2018, 34 (6):83.
760	79.	Yan J, Estanbouli H, Liao C, Kim W, Monk JM, Rahman R, Kamboj M, Palsson BO, Qiu W, Xavier
761	75.	JB: Systems-level analysis of NaID mutation, a recurrent driver of rapid drug resistance in
762		acute <i>Pseudomonas aeruginosa</i> infection. <i>PLoS Comput Biol</i> 2019, 15 (12):e1007562.
763	80.	Sobel ML, Neshat S, Poole K: Mutations in PA2491 (mexS) promote MexT-dependent mexEF-
764	80.	oprN expression and multidrug resistance in a clinical strain of <i>Pseudomonas aeruginosa</i> . J
765		Bacteriol 2005, 187 (4):1246-1253.
765	81.	Juarez P, Broutin I, Bordi C, Plésiat P, Llanes C: Constitutive activation of mexT by amino acid
	ο1.	
767 768		substitutions results in MexEF-OprN overproduction in clinical isolates of <i>Pseudomonas</i>
768 769	82.	<i>aeruginosa</i> . Antimicrobial agents and chemotherapy 2018, 62 (5). Llanes C, Köhler T, Patry I, Dehecq B, van Delden C, Plésiat P: Role of the MexEF-OprN efflux
	02.	system in low-level resistance of <i>Pseudomonas aeruginosa</i> to ciprofloxacin. Antimicrobial
770 771		
771		agents and chemotherapy 2011, 55 (12):5676-5684.

 Guénard S, Muller C, Monlezun L, Benas P, Broutin I, Jeannot K, Plésiat P: Multiple mutations lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of <i>Pseudomonas aeruginosa.</i> Antimicrobial agents and chemotherapy 2014, 58(1):221-228. Chuanchuen R, Wannaprasat W, Ajariyakhajorn K, Schweizer HP: Role of the MexXY multidrug efflux pump in moderate aminoglycoside resistance in <i>Pseudomonas aeruginosa</i> isolates from <i>Pseudomonas</i> mastitis. <i>Microbiology and immunology</i> 2008, 52(8):392-398. Hocquet D, Muller A, Blanc K, Plesiat P, Talon D, Monnet DL, Bertrand X. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of <i>Pseudomonas aeruginosa</i>. <i>Antimicrobiol agents and chemotherapy</i> 2008, 52(3):1173-1175. Islam S, Jalal S, Wretlind B: Expression of the MexXY efflux pump in amkacin-resistant isolates of <i>Pseudomonas aeruginosa</i>. <i>Clinical microbiology and infections Diseases</i> 2004, 10(10):877-883. Alvarez-Ortega C, Wlegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam <i>resistance</i>. <i>Antimicrobiol agents and chemotherapy</i> 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas eeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. <i>Antimicrobiol agents and chemotherapy</i> 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Miuzshima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 1999, 43(2):415-417. Poole K, Goth N, Tsujimot H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-oprJ</i> efflux operon in <i>nfxB</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1995, 21(2):172
 <i>Pseudomonas aeruginosa</i>. Antimicrobial agents and chemotherapy 2014, 58(1):221-228. Chuanchuen R, Wannaprasat W, Ajańyakhajorn K, Schweizer HP: Role of the MexXY multidrug efflux pump in moderate aminoglycoide resistance in <i>Pseudomonas aeruginosa</i> isolates from <i>Pseudomonas</i> mastitis. <i>Microbiology and immunology</i> 2008, 52(8):392-398. Hocquet D, Muller A, Blanc K, Plesiat P, Talon D, Monnet DL, Bertrand X. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of <i>Pseudomonas aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 2008, 52(3):1173-1175. Islam S, Jalal S, Wretlind B: Expression of the MexXY efflux pump in amikacin-resistant isolates of <i>Pseudomonas aeruginosa</i>. <i>Clinical Microbiology and Infections</i>: the official <i>publication of the European Society of Clinical Microbiology and Infectious Diseases</i> 2004, 10(10):877-883. Alvare: Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. <i>Antimicrobial agents and chemotherapy</i> 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S. Cloning and Sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mina T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump. MexXY, from <i>Pseudomonas aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Mishino T: Overexpression of the <i>mexC-mexD-aprl</i> efflux operon in <i>nfx8</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. Nishino T: Overexpression of the mexC-mexD-aprl efflux system
 St. Chuanchuen R, Wannaprasat W, Ajariyakhajom K, Schweizer HP: Role of the MexXY multidrug efflux pump in moderate aminoglycoside resistance in <i>Pseudomonas aeruginosa</i> isolates from <i>Pseudomonas maxitis. Microbiology and immunology</i> 2008, 52(8):392-398. Hocquet D, Muller A, Blanc K, Plesiat P, Talon D, Monnet DL, Bertrand X: Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of <i>Pseudomonas aeruginosa</i>. Attimicrobiol ogents and chemotherapy 2008, 52(3):1173-1175. Islam S, Jalal S, Wretlind B: Expression of the MexXY efflux pump in amikacin-resistant isolates of <i>Pseudomonas aeruginosa</i>. Clinical microbiology and Infection : the official publication of the European Society of Clinical Microbiology and Infections Diseases 2004, 10(10):877-883. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistance of <i>Pseudomonas aeruginosa</i> to beta-lactams. Virulence 2011, 2(2):144-146. Li XZ, Ma D, Livermore DM, Nikaido H: Role of efflux pump(s) in intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. Antimicrobial agents and chemotherapy 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore proverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. Antimicrobiol agents and chemotherapy 1999, 43(2):415-417. Poole K, Goth N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overspression of the mexC-mexD-oprI efflux operon in <i>nfx8</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. Mol Microbiol 1996, 21(1):13-13-214.
 efflux pump in moderate aminogiv coside resistance in <i>Pseudomonas aeruginosa</i> isolates from <i>Pseudomonas</i> mastitis. <i>Microbiology and immunology</i> 2008, 52(8):392-398. Hocquet D, Muller A, Blanc K, Pleisa P, Talon D, Monnet DL, Bertrand X: Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of <i>Pseudomonas aeruginosa</i>. <i>Antimicrobiol agents and chemotherapy</i> 2008, 52(3):1173-1175. Islam S, Jaals S, Wretlind B: Expression of the MexXY efflux pump in amikacin-resistant isolates of <i>Pseudomonas aeruginosa</i>. <i>Clinical microbiology and infection: the official</i> <i>publication of the European Society of Clinical Microbiology and Infectious Diseases</i> 2004, 10(10):877-883. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. <i>Antimicrobial agents and chemotherapy</i> 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mine T, Morita Y, Katoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. <i>Antimicrobiol agents and chemotherapy</i> 1996, 38(2):1713-724. Poole K, Micheá A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. <i>Antimicrobiol</i> 1995, 21(4):173-724. Sober A, Sota A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. <i>Antimicrobio</i>
 from Pseudomonas mastitis. Microbiology and immunology 2008, 52(8):392-398. Hocquet D, Muller A, Blanc K, Plesiat P, Talon D, Monnet DL, Bertrand X: Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 2008, 52(3):1173-1175. Islam S, Jalal S, Wretlind B: Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004, 10(10):877-883. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrobial agents and chemotherapy 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the signaport and chemotherapy 1994, 38(8):1742-1752. Poole K, Heinrich SDE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the sideophore pyoverdine. Mol Microbiol 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the mexC-mexD-oprJ efflux operon in fn8-type multidrug- resistant strains of Pseudom
 Hocquet D, Muller A, Blanc K, Plesiat P, Talon D, Monnet DL, Bertrand X: Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of <i>Pseudomonas aeruginosa</i>. Antimicrobial agents and chemotherapy 2008, 52(3):1173-1175. Islam S, Jalal S, Wretlind B: Expression of the MexXY efflux pump in amikacin-resistant isolates of <i>Pseudomonas aeruginosa</i>. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004, 10(10):877-883. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. Antimicrobial agents and chemotherapy 1994, 38(8):1742-1752. Bole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mezD-oprl</i> efflux optero in <i>nfxB-type</i> multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. Mol Microbiol 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pecher JC: Characterization of <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting the <i>ecfX</i> and the gyr8 genes. <i>Diag Microbiol</i> 1996, 63(2):127-131. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS</i>, <i>mut1</i> and <i>uvD</i> genes) in <i>Pseudomonas aeruginosa</i>: molecular characterization of Anathys. Moltridge D, Blanc
 between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of <i>Pseudomonas aeruginosa</i>. Antimicrobiola gents and chemothrapy 2008, 52(3):1173-1175. Islam S, Jalal S, Wretlind B: Expression of the MexXY effux pump in amikacin-resistant isolates of <i>Pseudomonas aeruginosa</i>. Clinical Microbiology and Infectious Diseases 2004, 10(10):877-883. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistame of <i>Pseudomonas aeruginosa</i> to beta-lactams. Virulence 2011, 2(2):144-146. IX Z, Ma D, Livermore DM, Nikaido H: Role of efflux pump(s) in intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. Antimicrobial agents and chemotherapy 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore proverdine. Mol Microbiol 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the mexC-mexD-oprJ efflux openo in nfx8-type multidrug resistant strains of <i>Pseudomonas aeruginosa</i>. Mol Microbiol 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas</i> <i>aeruginosa</i>. Mol Microbiol 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> maginosa. Integra typeser (mut5, mut1 and uvrD genes) in <i>Pseudomonas aeruginosa</i>. molecular characteriza
 of Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 2008, 52(3):1173-1175. Islam S, Jalal S, Wretlind B: Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa. Clinical Microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004, 10(10):877-883. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistame of <i>Pseudomonas aeruginosa</i> to beta-lactams. Virulence 2011, 2(2):144-146. Ei XZ, Ma D, Livermore DM, Nikaido H: Role of efflux pump(s) in intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. Antimicrobial agents and chemotherapy 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. Mol Microbiol 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-oprJ</i> efflux operon in <i>nfx8</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. Mol Microbiol 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pecher JC: Characterization of <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting the <i>efX</i> and the <i>gyrB</i> genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131.
 Islam S, Jalal S, Wretlind B: Expression of the MexXY efflux pump in amikacin-resistant isolates of <i>Pseudomonas aeruginosa</i>. Clinical microbiology and Infectious Diseases 2004, 10(10):877-883. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistome of <i>Pseudomonas aeruginosa</i> to beta-lactams. Virulence 2011, 2(2):144-146. Li XZ, Ma D, Livermore DM, Nikaido H: Role of efflux pump(s) in intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. Antimicrobial agents and chemotherapy 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXV, from <i>Pseudomonas aeruginosa</i>. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-oprl</i> efflux operon in <i>nfx8</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i>: molecular characterization of naturally occurring mutants. <i>Mol Microbiol</i> 2002, 43(6):161-1610. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS, mutL</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i>: molecular (harchoio-01715). Buhl M, K
 isolates of Pseudomonas aeruginosa. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004, 10(10):877-883. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistance of <i>Pseudomonas aeruginosa</i> to beta-lactams. Virulence 2011, 2(2):144-146. Li XZ, Ma D, Livermore DM, Nikaido H: Role of efflux pump(s) in Intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. <i>Antimicrobiol agents and chemotherapy</i> 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the sideorphore pyoverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-oprl</i> efflux operon in <i>nfxB</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of <i>MexE-MexF-OprN</i>, a positively regulated multidrug efflux system of <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting the <i>ecfX</i> and the gyrB genes. <i>Diagn Microbiol Infect Dis</i> 2009, 63(2):127-131. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>muts, mut1 and uvD</i> genes) in <i>Pseudomonas aeruginosa</i>:
 isolates of Pseudomonas aeruginosa. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004, 10(10):877-883. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistance of <i>Pseudomonas aeruginosa</i> to beta-lactams. Virulence 2011, 2(2):144-146. Li XZ, Ma D, Livermore DM, Nikaido H: Role of efflux pump(s) in Intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. <i>Antimicrobiol agents and chemotherapy</i> 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the sideorphore pyoverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-oprl</i> efflux operon in <i>nfxB</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of <i>MexE-MexF-OprN</i>, a positively regulated multidrug efflux system of <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting the <i>ecfX</i> and the gyrB genes. <i>Diagn Microbiol Infect Dis</i> 2009, 63(2):127-131. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>muts, mut1 and uvD</i> genes) in <i>Pseudomonas aeruginosa</i>:
 10(10):877-883. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistome of <i>Pseudomonas aeruginosa</i> to beta-lactams. <i>Virulence</i> 2011, 2(2):144-146. Li XZ, Ma D, Livermore DM, Nikaido H: Role of efflux pump(s) in intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. <i>Antimicrobial agents and chemotherapy</i> 1994, 38(3):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-aprl</i> efflux operon in <i>nfxB</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pecher BC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginoss</i> by a duplex real-time polymerase chain reaction assay targeting the <i>ecfx</i> and the <i>gyrB</i> genes. <i>Diagn Microbiol Infect Dis</i> 2009, 63(2):127-131. Oliver A, Baquero F, Bläquez J: The mismatch repair system (mut5, mut1 and uvrD genes) in <i>Pseudomonas aeruginosa</i> molecular characterization of naturally occurring mutants. <i>Mol Microbiol</i> 2002, 43(6):1641-1650. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM
 Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistome of <i>Pseudomonas aeruginosa</i> to beta-lactams. <i>Virulence</i> 2011, 2(2):144-146. Li XZ, Ma D, Livermore DM, Nikaido H: Role of efflux pump(s) in intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. <i>Antimicrobial agents and chemotherapy</i> 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-oprl</i> efflux operon in <i>nfxB</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> molecular characterization of anturally occurring mutants. <i>Mol Microbiol</i> 2002, 43(6):1641-1650. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS</i>, mut1 and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i>: molecular characterization of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>: molecular characterization of cRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>: mBio 2015, 6(6):e01796-01715. Buhl M,
 Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: The intrinsic resistome of <i>Pseudomonas aeruginosa</i> to beta-lactams. <i>Virulence</i> 2011, 2(2):144-146. Li XZ, Ma D, Livermore DM, Nikaido H: Role of efflux pum(s) in intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. <i>Antimicrobial agents and chemotherapy</i> 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-optl</i> efflux operon in <i>nfx8</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> the alpha Microbiol 1997, 23(2):345-354. Oliver A, Baquero F, Blázquez J: The mismatch repair system (mut3, mut1 and uvrD genes) in <i>Pseudomonas aeruginosa</i> the delta lafave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>. mBio 2015, 6(6):e01796-01715. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: M
 Pseudomonas aeruginosa to beta-lactams. Virulence 2011, 2(2):144-146. Ii XZ, Ma D, Livermore DM, Nikaido H: Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: ative efflux as a contributing factor to beta-lactam resistance. Antimicrobial agents and chemotherapy 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. Mol Microbiol 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the mexC-mexD-oprl efflux operon in nfx8-type multidrug- resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of Pseudomonas aeruginosa ya duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131. Oliver A, Baquero F, Blázquez J: The mismatch repair system (mut5, mut1 and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002, 43(6):1641-1650. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyr
 Li XZ, Ma D, Livermore DM, Nikaido H: Role of efflux pump(s) in intrinsic resistance of <i>Pseudomonas aeruginosa</i>: active efflux as a contributing factor to beta-lactam resistance. <i>Antimicrobial agents and chemotherapy</i> 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-oprJ</i> efflux operon in <i>nfxB</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i>: molecular characterization of naturally occurring mutants. <i>Mol Microbiol</i> 2002, 43(6):1641-1650. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS</i>, <i>mutL</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i>: molecular characterization of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>. <i>mBio</i> 2015, 6(6):e01796-01715. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> strains from patients and hospital environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742. Cabot G, Ló
 Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrobial agents and chemotherapy 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. Mol Microbiol 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-oprJ</i> efflux operon in <i>nfxB</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. Mol Microbiol 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> to ya duplex real-time polymerase chain reaction assay targeting the <i>ecfX</i> and the gyrB genes. <i>Diagn Microbiol Infect Dis</i> 2009, 63(2):127-131. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS, mutL</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i>: molecular characterization of naturally occurring mutants. <i>Mol Microbiol</i> 2002, 43(6):1641-1650. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant <i>Pse</i>
 Antimicrobial agents and chemotherapy 1994, 38(8):1742-1752. Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. Mol Microbiol 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-oprl</i> efflux operon in <i>nfxB</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. Mol Microbiol 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas</i> <i>aeruginosa</i>. Mol Microbiol 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i>: molecular characterization of <i>Interofical and the gyrB</i> genes. <i>Diagn Microbiol Infect Dis</i> 2009, 63(2):127-131. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS, mutL</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i>: molecular characterization of cRISPR-Cas systems in antibiotic- resistant Pseudomonas aeruginosa. <i>mBio</i> 2015, 6(6):e01796-01715. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> atrains from patients and hospital environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742. Cabot G, López-Caus
 Poole K, Heinrichs DE, Neshat S: Cloning and sequence analysis of an EnvCD homologue in <i>Pseudomonas aeruginosa</i>: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. <i>Mol Microbiol</i> 1993, 10(3):529-544. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in <i>Escherichia coli</i> of a new multidrug efflux pump, MexXY, from <i>Pseudomonas aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-oprJ</i> efflux operon in <i>nfxB</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechere JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting the <i>ecfX</i> and the <i>gyrB</i> genes. <i>Diagn Microbiol Infect Dis</i> 2009, 63(2):127-131. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS, mutl</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i>. molecular characterization of naturally occurring mutants. <i>Mol Microbiol</i> 2002, 43(6):1641-1650. Yan Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>. <i>mBio</i> 2015, 6(6):e01796-01715. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> strains from patients and hospital environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742
 Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. Mol Microbiol 1993, 10(3):529-544. 90. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. 91. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug- resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996, 21(4):713-724. 92. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997, 23(2):345-354. 93. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131. 94. Oliver A, Baquero F, Blázquez J: The mismatch repair system (muts, mut1 and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002, 43(6):1641-1650. 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G et al: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant Pseudomonas aeruginosa. mBio 2015, 6(6):e01796-0175. 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742. 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau
 the siderophore pyoverdine. Mol Microbiol 1993, 10(3):529-544. 90. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. 91. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996, 21(4):713-724. 92. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997, 23(2):345-354. 93. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131. 94. Oliver A, Baquero F, Blázquez J: The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002, 43(6):1641-1650. 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G et al: Phylogenetic distribution of CRISPR-Cas systems in antibiotic-resistant Pseudomonas aeruginosa. mBio 2015, 6(6):e01796-01715. 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742. 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
 90. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. 91. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the mexC-mexD-oprl efflux operon in nfx8-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996, 21(4):713-724. 92. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997, 23(2):345-354. 93. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131. 94. Oliver A, Baquero F, Blázquez J: The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002, 43(6):1641-1650. 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G et al: Phylogenetic distribution of CRISPR-Cas systems in antibiotic-resistant Pseudomonas aeruginosa: mBio 2015, 6(6):e01796-01715. 96. Buhl M, Kästle C, Geyer A, Autenrieh IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742. 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
 multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the mexC-mexD-oprJ efflux operon in nfx8-type multidrug- resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996, 21(4):713-724. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131. Oliver A, Baquero F, Blázquez J: The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002, 43(6):1641-1650. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G et al: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant Pseudomonas aeruginosa. mBio 2015, 6(6):e01796-01715. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
 <i>chemotherapy</i> 1999, 43(2):415-417. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the <i>mexC-mexD-oprJ</i> efflux operon in <i>nfxB</i>-type multidrug- resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. P2. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. P3. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting the <i>ecfX</i> and the <i>gyrB</i> genes. <i>Diagn Microbiol Infect Dis</i> 2009, 63(2):127-131. P4. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS</i>, <i>mutL</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i>: molecular characterization of naturally occurring mutants. <i>Mol Microbiol</i> 2002, 43(6):1641-1650. P5. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>. <i>mBio</i> 2015, 6(6):e01796-01715. P6. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> strains from patients and hospital environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742. P7. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B <i>et al</i>: Deciphering the resistome of the widespread
 Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T: Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug- resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996, 21(4):713-724. 92. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997, 23(2):345-354. 93. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131. 94. Oliver A, Baquero F, Blázquez J: The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002, 43(6):1641-1650. 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G et al: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant Pseudomonas aeruginosa. mBio 2015, 6(6):e01796-01715. 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742. 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
 Nishino T: Overexpression of the mext-mexD-oprJ efflux operon in nfxB-type multidrug- resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996, 21(4):713-724. 92. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997, 23(2):345-354. 93. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131. 94. Oliver A, Baquero F, Blázquez J: The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002, 43(6):1641-1650. 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G et al: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant Pseudomonas aeruginosa. mBio 2015, 6(6):e01796-01715. 811 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742. 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
 resistant strains of <i>Pseudomonas aeruginosa</i>. <i>Mol Microbiol</i> 1996, 21(4):713-724. 92. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. 93. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting the <i>ecfX</i> and the <i>gyrB</i> genes. <i>Diagn Microbiol Infect Dis</i> 2009, 63(2):127-131. 94. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS, mutL</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i>: molecular characterization of naturally occurring mutants. <i>Mol Microbiol</i> 2002, 43(6):1641-1650. 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>. <i>mBio</i> 2015, 6(6):e01796-01715. 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> strains from patients and hospital environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742. 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B <i>et al</i>: Deciphering the resistome of the widespread
 799 92. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. 802 93. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting the <i>ecfX</i> and the <i>gyrB</i> genes. <i>Diagn Microbiol Infect Dis</i> 2009, 63(2):127-131. 805 94. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS, mutL</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i>: molecular characterization of naturally occurring mutants. <i>Mol</i> <i>Microbiol</i> 2002, 43(6):1641-1650. 808 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>. <i>mBio</i> 2015, 6(6):e01796-01715. 811 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> strains from patients and hospital environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742. 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B <i>et al</i>: Deciphering the resistome of the widespread
 MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Mol Microbiol</i> 1997, 23(2):345-354. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting the <i>ecfX</i> and the <i>gyrB</i> genes. <i>Diagn Microbiol Infect Dis</i> 2009, 63(2):127-131. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS, mutL</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i>: molecular characterization of naturally occurring mutants. <i>Mol</i> <i>Microbiol</i> 2002, 43(6):1641-1650. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>. <i>mBio</i> 2015, 6(6):e01796-01715. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> strains from patients and hospital environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B <i>et al</i>: Deciphering the resistome of the widespread
 801 aeruginosa. Mol Microbiol 1997, 23(2):345-354. 802 93. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of 803 Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting 804 the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131. 805 94. Oliver A, Baquero F, Blázquez J: The mismatch repair system (mutS, mutL and uvrD genes) in 806 Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol 807 Microbiol 2002, 43(6):1641-1650. 808 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, 809 Hannum G, Zambardi G et al: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- 810 resistant Pseudomonas aeruginosa. mBio 2015, 6(6):e01796-01715. 811 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of 812 extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital 813 environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742. 814 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan 815 C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
 Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131. Oliver A, Baquero F, Blázquez J: The mismatch repair system (mutS, mutL and uvrD genes) in <i>Pseudomonas aeruginosa</i>: molecular characterization of naturally occurring mutants. Mol Microbiol 2002, 43(6):1641-1650. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G et al: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant Pseudomonas aeruginosa. mBio 2015, 6(6):e01796-01715. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
 803 <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting 804 the <i>ecfX</i> and the <i>gyrB</i> genes. <i>Diagn Microbiol Infect Dis</i> 2009, 63(2):127-131. 805 94. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS, mutL</i> and <i>uvrD</i> genes) in 806 <i>Pseudomonas aeruginosa</i>: molecular characterization of naturally occurring mutants. <i>Mol</i> 807 <i>Microbiol</i> 2002, 43(6):1641-1650. 808 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, 809 Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- 810 <i>resistant Pseudomonas aeruginosa</i>. <i>mBio</i> 2015, 6(6):e01796-01715. 811 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of 812 <i>extensively drug-resistant (XDR) Pseudomonas aeruginosa</i> strains from patients and hospital 813 <i>environment in a prolonged outbreak</i>. <i>Frontiers in microbiology</i> 2019, 10:1742. 814 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan 815 C, Tubau F, Rodríguez C, Moyà B <i>et al</i>: Deciphering the resistome of the widespread
 the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131. Oliver A, Baquero F, Blázquez J: The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002, 43(6):1641-1650. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G et al: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant Pseudomonas aeruginosa. mBio 2015, 6(6):e01796-01715. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
 94. Oliver A, Baquero F, Blázquez J: The mismatch repair system (<i>mutS</i>, <i>mutL</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i>: molecular characterization of naturally occurring mutants. <i>Mol</i> <i>Microbiol</i> 2002, 43(6):1641-1650. 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>. <i>mBio</i> 2015, 6(6):e01796-01715. 811 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> strains from patients and hospital environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742. 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan K, Tubau F, Rodríguez C, Moyà B <i>et al</i>: Deciphering the resistome of the widespread
 806 Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol 807 Microbiol 2002, 43(6):1641-1650. 808 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, 809 Hannum G, Zambardi G et al: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- 810 resistant Pseudomonas aeruginosa. mBio 2015, 6(6):e01796-01715. 811 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of 812 extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital 813 environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742. 814 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan 815 C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
 Microbiol 2002, 43(6):1641-1650. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>. <i>mBio</i> 2015, 6(6):e01796-01715. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> strains from patients and hospital environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B <i>et al</i>: Deciphering the resistome of the widespread
 van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>. <i>mBio</i> 2015, 6(6):e01796-01715. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> strains from patients and hospital environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B <i>et al</i>: Deciphering the resistome of the widespread
 Hannum G, Zambardi G <i>et al</i>: Phylogenetic distribution of CRISPR-Cas systems in antibiotic- resistant <i>Pseudomonas aeruginosa</i>. <i>mBio</i> 2015, 6(6):e01796-01715. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> strains from patients and hospital environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B <i>et al</i>: Deciphering the resistome of the widespread
810resistant Pseudomonas aeruginosa. mBio 2015, 6(6):e01796-01715.81196.Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of812extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital813environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742.81497.Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan815C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
 811 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of 812 extensively drug-resistant (XDR) <i>Pseudomonas aeruginosa</i> strains from patients and hospital 813 environment in a prolonged outbreak. <i>Frontiers in microbiology</i> 2019, 10:1742. 814 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan 815 C, Tubau F, Rodríguez C, Moyà B <i>et al</i>: Deciphering the resistome of the widespread
812extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital813environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742.81497.Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan815C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
813environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742.81497.Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan815C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
814 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan 815 C, Tubau F, Rodríguez C, Moyà B <i>et al</i> : Deciphering the resistome of the widespread
815 C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
o to estimational metal and the sequence type to international nigh-fisk cione through whole-
817 genome sequencing. Antimicrobial agents and chemotherapy 2016, 60 (12):7415-7423.
818 98. CDC & FDA Antibiotic Resistance Isolate Bank for <i>Pseudomonas aeruginosa</i> [Available at:
819 <u>https://wwwn.cdc.gov/ARIsolateBank/Panel/PanelDetail?ID=12</u>
820 00 Demonstree D. Kindel UNA Le CE Cudius - U. D. Annual A. Desseli, D. Deste July - U. M. 11 D.
820 99. Ramanathan B, Jindal HM, Le CF, Gudimella R, Anwar A, Razali R, Poole-Johnson J, Manikam R,
 820 99. Ramanathan B, Jindal HM, Le CF, Gudimella R, Anwar A, Razali R, Poole-Johnson J, Manikam R, 821 Sekaran SD: Next generation sequencing reveals the antibiotic resistant variants in the 822 genome of <i>Pseudomonas aeruginosa</i>. <i>PLoS One</i> 2017, 12(8):e0182524.

823	100.	Tsang KK, Maguire F, Zubyk HL, Chou S, Edalatmand A, Wright GD, Beiko RG, McArthur AG:
824		Identifying novel β -lactamase substrate activity through <i>in silico</i> prediction of antimicrobial
825		resistance. Microbial genomics 2021, 7(1).
826	101.	Wardell SJT, Rehman A, Martin LW, Winstanley C, Patrick WM, Lamont IL: A large-scale whole-
827		genome comparison shows that experimental evolution in response to antibiotics predicts
828		changes in naturally evolved clinical Pseudomonas aeruginosa. Antimicrobial agents and
829		chemotherapy 2019, 63 (12).
830	102.	Cortes-Lara S, Barrio-Tofiño ED, López-Causapé C, Oliver A, Gemara-Seimc Reipi Pseudomonas
831		study Group: Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole
832		genome sequence resistome analysis. Clinical microbiology and infection : the official
833		publication of the European Society of Clinical Microbiology and Infectious Diseases 2021,
834		27 (11):1631-1637.
835	103.	Sun Z, Yang F, Ji J, Cao W, Liu C, Ding B, Xu X: Dissecting the genotypic features of a
836		fluoroquinolone-resistant Pseudomonas aeruginosa ST316 sublineage causing ear infections
837		in Shanghai, China. Microbial genomics 2023, 9 (4).
838	104.	Su M, Satola SW, Read TD: Genome-based prediction of bacterial antibiotic resistance.
839		Journal of clinical microbiology 2019, 57 (3):e01405-01418.
840	105.	Madden DE, McCarthy KL, Bell SC, Olagoke O, Baird T, Neill J, Ramsay KA, Kidd TJ, Stewart AG,
841		Subedi S et al: Rapid fluoroquinolone resistance detection in Pseudomonas aeruginosa using
842		mismatch amplification mutation assay-based real-time PCR. J Med Microbiol 2022,
843		71 (10):001593.
844	106.	Madden DE, Olagoke O, Baird T, Neill J, Ramsay KA, Fraser TA, Bell SC, Sarovich DS, Price EP:
845		Express yourself: Quantitative real-time PCR assays for rapid chromosomal antimicrobial
846		resistance detection in <i>Pseudomonas aeruginosa</i> . Antimicrobial agents and chemotherapy
847	_	2022, 66 (5):e0020422.
848	107.	Mobegi FM, Cremers AJ, de Jonge MI, Bentley SD, van Hijum SA, Zomer A: Deciphering the
849		distance to antibiotic resistance for the pneumococcus using genome sequencing data. Sci
850		Rep 2017, 7 :42808.
851	108.	Sarovich DS, Price EP: SPANDx: a genomics pipeline for comparative analysis of large haploid
852		whole genome re-sequencing datasets. BMC research notes 2014, 7:618.
853	109.	Crouch DJM, Bodmer WF: Polygenic inheritance, GWAS, polygenic risk scores, and the search
854	110	for functional variants. Proc Natl Acad Sci U S A 2020, 117 (32):18924-18933.
855	110.	ARDaP - Antimicrobial Resistance Detection and Prediction.
856		[https://github.com/dsarov/ARDaP]
857	111.	Sherry NL, Horan KA, Ballard SA, Gonızalves da Silva A, Gorrie CL, Schultz MB, Stevens K,
858		Valcanis M, Sait ML, Stinear TP <i>et al</i> : An ISO-certified genomics workflow for identification
859		and surveillance of antimicrobial resistance. Nat Commun 2023, 14 (1):60.
860	112.	Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH, Zhao S, Hsu CH,
861		McDermott PF et al: Validating the AMRFinder tool and resistance gene database by using
862		antimicrobial resistance genotype-phenotype correlations in a collection of isolates.
863	442	Antimicrobial agents and chemotherapy 2019, 63 (11):e00483-00419.
864	113.	Bekkar M, Djemaa HK, Alitouche TA: Evaluation measures for models assessment over
865		imbalanced data sets. J Inf Eng Appl 2013, 3 (10):27-38.
866	114.	Hicks AL, Wheeler N, Sanchez-Buso L, Rakeman JL, Harris SR, Grad YH: Evaluation of
867		parameters affecting performance and reliability of machine learning-based antibiotic
868		susceptibility testing from whole genome sequencing data. PLoS Comput Biol 2019,
869	445	15(9):e1007349.
870 871	115.	Van Goethem N, Descamps T, Devleesschauwer B, Roosens NHC, Boon NAM, Van Oyen H,
871 872		Robert A: Status and potential of bacterial genomics for public health practice: a scoping
872 872	110	review. Implement Sci 2019, 14(1):79.
873 874	116.	Kidd TJ, Ritchie SR, Ramsay KA, Grimwood K, Bell SC, Rainey PB: <i>Pseudomonas aeruginosa</i> exhibits frequent recombination, but only a limited association between genotype and
874 875		
0/5		ecological setting. PLoS One 2012, 7(9):e44199.

876	117.	Matuschek E, Ahman J, Webster C, Kahlmeter G: Antimicrobial susceptibility testing of
877		colistin - evaluation of seven commercial MIC products against standard broth microdilution
878		for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter
879		spp. Clinical microbiology and infection : the official publication of the European Society of
880		Clinical Microbiology and Infectious Diseases 2018, 24 (8):865-870.
881	118.	Bassetti M, Vena A, Croxatto A, Righi E, Guery B: How to manage Pseudomonas aeruginosa
882		infections. Drugs Context 2018, 7:212527.
883	119.	Gurjar M: Colistin for lung infection: an update. J Intensive Care 2015, 3(1):3.
884	120.	Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J: Utilization of colistin for
885		treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol
886		2008, 19 (6):413-418.
887	121.	Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in
888		Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol
889		2012, 302 (2):63-68.
890	122.	Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C,
891		Pena C, Martinez-Martinez L <i>et al</i> : Overexpression of <i>AmpC</i> and efflux pumps in
892		Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on
893		resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011,
894		55 (5):1906-1911.
895	123.	Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and
896		metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South
897		Korea. International journal of antimicrobial agents 2012, 40 (2):168-172.
898	124.	Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta-
899		lactamases from non-fermenting and other Gram-negative opportunistic pathogens. FEMS
900		Microbiol Rev 2017, 41 (6):781-815.
901	125.	Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses.
902		Nature Medicine 2004, 10 (12S):S122-S129.
903	126.	Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i> : A small
904		RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility.
905		Mol Ther Nucleic Acids 2019, 16 :218-228.
906	127.	Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC:
907		Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside
908		acetyltransferase. Nat Med 2006, 12 (1):83-88.
909	128.	Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A,
910		Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-
911		Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower
912		Respiratory Tract Infection Trial. Journal of clinical microbiology 2020, 58(7).
913	129.	Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide
914		identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i>
915		<i>aeruginosa</i> . Antimicrobial agents and chemotherapy 2009, 53 (6):2522-2531.
916		

917 Tables

918 Table 1. Summary of antimicrobial resistance prevalence across 10 clinically relevant antibiotics in

919 the Pseudomonas aeruginosa Global Dataset

Antibiotic Class	Antibiotic	Res (%)	Int (%)	Sen (%)	No. isolates
Carbananama	MEM	682 (36)	149 (8)	682 (36)	1875
Carbapenems	IPM	186 (29)	46 (7)	419 (64)	651
Polymyxins	CST	48 (5)	0 (0)	933 (95)	981
Fluoroquinolones	CIP	664 (54)	78 (6)	477 (39)	1219
Cephalosporins	FEP	157 (17)	111(12)	650 (71)	918
Cephalosponns	CAZ	316 (27)	121 (10)	733 (63)	1170
Penicillins	TZP	179 (24)	52 (7)	526 (69)	757
r enicinins	PIP	185 (36)	55 (11)	272 (53)	512
Aminoglycosides	ТОВ	294 (29)	12 (1)	695 (69)	1001
Anniogycosides	АМК	170 (12)	56 (4)	1199 (84)	1425

920

921 Abbreviations: Res, resistant; Int, intermediate; Sen, sensitive; MEM, meropenem; IPM, imipenem;

922 CST, colistin; CIP, ciprofloxacin; FEP, cefepime; CAZ, ceftazidime, TZP, piperacillin/tazobactam; PIP,

923 piperacillin; TOB, tobramycin; AMK, amikacin

924 Table 2. Novel antimicrobial resistance (AMR) variants identified in *Pseudomonas aeruginosa* by

925 microbial genome-wide association study (mGWAS) or comparative genomic[®] analyses

Locus	Type of mutation	Associated AMR phenotype	Fisher's Exact <i>p</i> value
PA0027	Lys34Asn	PIPr	< 0.0001
PA0091 (vgrG1)	Gln214His	АМКі	NA
PA0746	Lys106Asn	FEPr	< 0.0001
PA0958 (oprD)	Thr18fs ^{®^}	MEMr, IPMr	NA
PA0958 (oprD)	Phe36fs ^{₽^}	MEMr, IPMr	NA
PA0958 (oprD)	Leu136Gln [®]	MEMr	NA
PA0958 (oprD)	Gly139fs ^{®^}	MEMr, IPMr	NA
PA0958 (oprD)	Gly193fs ^{⊉^}	MEMr, IPMr	NA
PA0958 (oprD)	Tyr199fs ^{®^}	MEMr, IPMr	NA
PA0958 (oprD)	Gln340Pro [®]	MEMr	NA
PA0958 (oprD)	Tyr350fs ^{≅^}	MEMr, IPMr	NA
PA0958 (oprD)	Leu355fs [™]	MEMr, IPMr	NA
PA0958 (oprD)	Leu409Pro [®]	MEMr	NA
PA1430 (lasR)	Glu183Gly [®]	CSTr	NA
PA1456 (cheY)	Val81Ala	CSTr	NA
PA1760	LOF [₽]	ТZРі	NA
PA1798 (parS)	Ala149Thr	MEMr	< 0.0001
PA1798 (parS)	Arg383Cys [®]	CSTr	NA
PA1798 (parS)	Arg7His [®]	PIPr	NA
PA1798 (parS)	Asp249Asn [®]	TZPr, AMKi	NA
PA1799 (parR)	Val68Ala	CAZr	0.0002
PA1799 (parR)	Leu165Phe [®]	MEMr	NA
PA1923	Ala350Val	TZPr	< 0.0001
PA1942 ¹	LOF	MEMr, IPMr	NA
PA2020 (mexZ)	Thr32Asn [®]	MEMr	NA
PA2020 (mexZ)	Ser198lle [₽]	MEMr	NA
PA2020 (mexZ)	Leu199Arg [®]	FEPr	NA
PA2402	Val3040Ala	AMKr	< 0.0001
PA2520 (czcA)	Gly1051Asp [®]	CSTr	NA
PA2736	Arg30Gly	AMKr	< 0.0001
РАЗО47 (РВР4, dacB)	Thr27Ser	CAZr, FEPr, PIPr, TZPr	NA
PA3047 (PBP4, dacB)	Ser230lle	CAZr, FEPr, PIPr, TZPr	NA
PA3047 (PBP4, dacB)	Phe438Leu	CAZr, FEPr, PIPr, TZPr	NA
PA3083 (pepN)	LOF [₽]	MEMr, CAZr	NA
PA3384 (phnC)	LOF	MEMr, TOBr	NA
PA3574 (nalD)	Leu76Pro [®]	MEMr	NA
PA3574 (nalD)	Arg164Pro [®]	PIPr, FEPr	NA
PA3721 (nalC)	Lys58Glu [®]	MEMr	NA
PA4020 (mpl)	Gly137Ser [®]	CAZr	NA

PA4109 (ampR)	Ter297Tyr stop lost ^{≅^}	PIPr	NA
PA4110 (ampC)	Asp272Asn [®]	MEMr	NA
PA4110 (ampC) ²	Leu320Pro [®]	MEMr	NA
PA4260 (rplB)	Gly138Ser [®]	TOBi, AMKr	NA
PA4266 (fusA1) [#]	Ser459Phe [®]	TOBr, AMKr	NA
PA4296 (pprB)	Asn253His [®]	CSTr	NA
PA4318	Pro243Ser	PIPr	< 0.0001
PA4418 (ftsl)	Gly63Asp [®]	IPMr, CAZr, FEPr, TZPr, PIPr	NA
PA4522 (ampD)	Val10Gly [₽]	CAZr, FEPi, PIPi	NA
PA4522 (ampD)	Pro41Leu [®]	PIPr, FEPr	NA
PA4522 (ampD)	Glu67stop ^{®^}	CAZi, MEMi, IPMi, TZPi, PIPi, FEPi	NA
PA4522 (ampD)	lle69Thr [®]	MEMr	NA
PA4522 (ampD)	Gln88Leu [®]	CAZr	NA
PA4522 (ampD)	Gly100Glu [₽]	MEMr	NA
PA4522 (ampD)	Cys110Gly [₽]	FEPr	NA
PA4522 (ampD)	Gly116Val [®]	MEMr, CAZr	NA
PA4522 (ampD)	lle117Thr [®]	CAZr	NA
PA4522 (ampD)	Gly121Glu [₽]	MEMr, CAZi	NA
PA4522 (ampD)	His157Tyr [®]	CAZr	NA
PA4522 (ampD)	Gly169Cys [®]	FEPr	NA
PA4599 (mexC)	-58C>A ^ℙ	FEPr	NA
PA4677	Asp138Val	FEPr	< 0.0001
PA4776 (pmrA)	Leu72Phe [₽]	CSTr	NA
PA4777 (pmrB)	Arg10Leu [®]	CSTr	NA
PA4777 (pmrB)	Arg155His [®]	CSTr	NA
PA4777 (pmrB)	Thr158Ile [®]	CSTr	NA
PA4777 (pmrB)	Thr253Met [®]	CSTr	NA
PA5000 (wapR)	Gly163Asp [®]	CSTr	NA
PA4967 (parE)	Glu459Lys	CIPi	NA
PA4967 (parE)	Val520Ala	CIPi	NA
PA5045 (ponA)	Met671lle	CAZr, FEPr, TZPr, PIPr	NA
PA5051 (argS)	Asp184Gly	TOBr	NA
PA5199 (amgS)	Trp120Gly [®]	CSTr	NA
PA5199 (amgS)	Pro435Ala [®]	CSTr	NA
PA5338 (spoT)	Gly496Ser [®]	CAZr	NA
PA5493 (polA)	Lys395Arg	AMKr	NA

926 Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; FEP, cefepime; fs,

927 frameshift; i, intermediate resistant; IPM, imipenem; LOF, loss of function; MEM, meropenem; NA, not

928 applicable; PIP, piperacillin; r, resistant; TOB, tobramycin; TZP, piperacillin/tazobactam

¹Previously predicted to cause PIPr [129]; however, our microbial genome-wide associate study

- 930 (mGWAS) analysis did not identify a significant association with this phenotype. Instead, mGWAS
- 931 showed that this AMR variant was significantly associated with MEMr.


932 ²Previously identified variant in *ampC* known to reduce susceptibility to multiple cephalosporins.


933 ^BVariant identified by comparative genomics and thus not assessed for statistical significance.

[#]Identified in the Validation Dataset only.


935 [^]High-consequence mutations occurring in this gene are automatically identified by ARDaP.

936 Figures





- 944 amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; FEP, cefepime; FQs, fluoroquinolones; IPM,
- 945 imipenem; MEM, meropenem; PIP, piperacillin; TZP, piperacillin/tazobactam; TOB, tobramycin. *No
- 946 strains in the Validation Dataset exhibited CST AMR; as such, balanced accuracy could not be



947 calculated for this antibiotic.

949 Figure 2. Precision and recall of ARDaP, abritAMR, AMRFinderPlus, and ResFinder across the Global


950 Dataset (*n*=1877 strains). Precision and recall metrics for both antimicrobial-sensitive and


- 951 antimicrobial-resistant strains were highest using ARDaP (A; range 73-96%) with abritAMR (B; range
- 952 54-62%), AMRFinderPlus (B; range 55-62%) and ResFinder (C; range 42-68%) all performing worse in


953 comparison. To enable comparison with existing AMR prediction software, isolates with intermediate


- 954 AMR were removed prior to analysis. Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP,
- 955 ciprofloxacin; CST, colistin; FEP, cefepime; FQs, fluoroquinolones; IPM, imipenem; MEM, meropenem;
- 956 PIP, piperacillin; TZP, piperacillin/tazobactam; TOB, tobramycin. N.B. Precision (resistance) is also
- 957 known as positive predictive value (PPV) and precision (sensitivity) is also known as negative predictive


958 value (NPV).











Precision (AMR) Recall (AMR)

Precision (sensitivity)